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 Physiologic changes in the body can drastically affect the clearance of a 
medication, and therefore increase the variability in exposure to the medication. 
Physiologic changes that can have a profound effect on the exposure of a medication can 
stem from changes CYP enzymes, transport proteins, binding protein expression, organ 
function, immune reactivity, and health status to name a few; with the focus of this 
dissertation on the dynamic changes in the ontogeny of MRP2 (an apical liver transport 
protein) and the dynamic changes caused by an immune response to a therapeutic 
monoclonal antibody (mAb). Several approaches can be used to limit or capture the 
changes in the pharmacokinetics of a medication caused by ontogeny and immune 
reactivity related dynamic changes. Three approaches were investigated in this 
dissertation: 1) preventing/limiting immunogenicity’s effect on a therapeutic mAb, hence 
eliminating the increase in clearance and variability, 2) using a pharmacometric PK-ADA
modeling approach to model immunology-related dynamic and variable effects on a
therapeutic mAb and 3) using a systems pharmacology strategy to model the ontogeny 
changes in a transport protein (MRP2) and the dynamic effects on its drug substrates. 
In the preclinical and clinical setting, anti-drug antibodies (ADA) that develop 
against therapeutic mAbs can influence patient safety and interfere with product efficacy.  
Thus, my first focus in this dissertation investigates methods to limit/prevent 
immunogenicity and therefore help to eliminate a source of variability and clearance that 
can be seen in preclinical and clinical studies. My first study investigates the use of 
immune suppressants in mitigating ADA responses to a fully-humanized mAb in 
preclinical animal studies. Three groups of Sprague Dawley rats (n=18) were treated with 
low (0.01 mg/kg), moderate (50 mg/kg), or high (300 mg/kg) doses of a mAb.  
Experimental groups also received either methotrexate or tacrolimus/sirolimus immune 
suppression. Methotrexate significantly lowered the incidence of anti-variable region 
antibodies at moderate mAb dose (P<0.05), while tacrolimus/sirolimus did likewise at 
moderate and high doses (P<0.01) of mAb. With the exception of low dose mAb plus 
methotrexate, all immunosuppressed groups displayed more than a 70-fold decrease in 
ADA magnitude (P<0.05). This abrogation in ADA response correlated with higher mAb
exposure in the circulation by week 4 for the moderate and high dosed mAb groups. This 
method provides an approach to mitigate preclinical immunogenicity by the use of 
immunosuppressant modalities. Such preconditioning can support preclinical drug 
development of human therapeutics that are antigenic to animals but not necessarily to 
humans.  Similar approaches to reduce immunogenicity will likely play an essential role 
with advances in novel therapeutics like fully human mAbs, recombinant proteins, fusion 
proteins as well as bispecific- and drug-conjugated antibodies. 
In some cases there may not be a method to reduce/eliminate immunogenicity and 
the dynamic changes in the elimination of a therapeutic mAb that result. In a preclinical 
setting, ADA typically influences both multiple dose toxicity studies, as well as 
preliminary pharmacokinetic (PK) analysis by leading to an increase in clearance of the 
therapeutic mAb. This increase in clearance caused by ADA can be highly variable due 
vi 
to each animal’s polyclonal immune response to a therapeutic mAb.  My second focus 
aims to account for ADA and its variable effect on a fully human therapeutic mAb. I used
data acquired from our previous study that investigated the use of immunosuppressant 
therapy in mitigating ADA responses to a mAb in a preclinical Sprague Dawley rat study 
and incorporated much of the data from that study, which included three mAb dosing 
groups and three immunomodulation therapies. A pharmacometric PK-ADA modeling 
approach was used to analyze the data. Our model was able to simultaneously capture the 
pharmacokinetics of the mAb in the presence and absence of ADA, accounting for an 
immune reaction’s highly variable effect on a therapeutic mAb concentration-time 
profile. The pharmacometric PK-ADA methodology used in this study demonstrates a 
modeling strategy that can be applied to other therapeutic mAbs to assess the 
immunogenicity of a therapeutic mAb and the dynamic effect immunogenicity has on the 
pharmacokinetics. This modeling methodology can further be applied to the simulation of 
therapeutic mAbs in the presence of varying rates, magnitudes and affinities of ADA
reactions, aiding in the development of appropriately powered toxicology studies and an 
accurate pharmacokinetic evaluation of a human therapeutic mAb in a preclinical setting. 
Transport proteins play an important role in determining the disposition of 
medications in the human body. The expression of transport proteins in the body is not 
constant throughout childhood development, which affects the pharmacokinetics of a 
medication that is a substrate of the transport protein. Multidrug resistance protein 2 
(MRP2) represents a major hepatic transporter whose expression is dynamic throughout 
development. MRP2 plays a vital role in the biliary excretion of various organic anions 
and cations along with glutathione-, glucuronate-, or sulfate-conjugates of several drug 
substrates. Our third aim is to evaluate the effect the ontogeny of MRP2 has on the 
pharmacokinetics of ceftriaxone to better understand how a transport protein contributes 
to the disposition of its substrates throughout childhood development. In order to 
accomplish our aim, a systems pharmacology modeling approach was used to understand 
MRP2’s contribution to the elimination of ceftriaxone and the effect of ontogeny changes 
on the pharmacokinetics of ceftriaxone in pediatric patients. Data from ex vivo studies, 
preclinical in vivo studies and clinical studies were used to inform our model. Results 
from the study demonstrate the contribution of MRP2 to the pharmacokinetics of 
ceftriaxone. Our model was able to capture ceftriaxone’s pharmacokinetics, and MRP2’s
contribution to its clearance, allowing for the prediction of pediatric ceftriaxone 
concentrations. This modeling strategy can also be used to evaluate ontogeny changes in 
other biochemical transposition proteins, and the subsequent effect on the 
pharmacokinetics of other therapeutically used compounds.  
In summary, our work has successfully provided approaches to limit/prevent 
dynamic changes caused by immune reactions to a therapeutic mAb, demonstrate a
pharmacometric PK-ADA approach that can capture the PK changes and variability 
caused by ADA formation on a therapeutic mAb and demonstrate a systems 
pharmacology model approach which accounts for the ontogeny of a transport protein 
and the resultant PK effects on its substrate through childhood development. The 
following chapters describe and discuss these novel approaches. 
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Interest in monoclonal antibodies (mAbs) as medications for therapeutic use has 
continuously grown over the last 25 years. Increasing research efforts are focusing on 
developing mAbs against various disease states including multiple cancer indications and 
chronic inflammatory conditions. At the current time, more than 40 mAbs have been 
approved by the Food and Drug Administration for marketing in the United States, and 
several dozens more are currently in clinical development.[1]  With this intense focus on 
mAbs in drug development programs and clinical practice, this tutorial is intended to 
outline and summarize some of the basic pharmacokinetic properties of this class of 
medications. 
?????????????? ??????
?
 All current clinically used therapeutic antibodies are immunoglobulin G (IgG) 
mAbs and possess the same basic structure (??????????): they are large heterodimeric 
protein molecules with a molecular weight of approximately 150 kDa and are composed 
of four polypeptide chains, two identical heavy chains (50 kDa) and two light chains (25 
kDa). The heavy and light chains are held together by disulfide bonds to form a Y-shape 
consisting of constant domains (CH and CL) and variable domains (VH and VL). The two 
variable regions and the CH1 domains of the heavy chains comprise the antigen binding 
fragment (Fab) with each variable domain containing the complementarity-determining 
region, which is highly specific for the target antigen. The CH2 and CH3 domains of the 
heavy chain make up the Fc (fragment, crystallizable) region of the antibody and can 
bind to a variety of cell surface receptors, including the Fc? receptors and the neonatal Fc 
receptor (FcRn) on cells, as well as components of the complement system (i.e., 
complement C1q).  The IgG class is divided into four subclasses: IgG1, IgG2, IgG3, and 
IgG4.[2] Typically, IgG1 and IgG3 are potent triggers of effector mechanisms, whereas 
IgG2 and IgG4 will induce more subtle responses. However, each of these antibodies 
remain capable of neutralizing target antigens.[3] Currently marketed mAbs are 
predominantly IgG1, with a lesser degree of IgG2 and IgG4. The preference for one IgG 
class over the other is partially determined whether effector functions such as antibody-
dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) 
are desired for the mAb activity as well as other structural factors, but also by prior 
experience and availability of a particular IgG subclass in a company’s development 
portfolio.[4] 
Similar to other biologics, mAbs are produced batch-wise in living cells. As such, 
they are defined by the production process rather than their chemical structure, and batch-
to-batch variability in the resulting product is well recognized and needs to be tightly 
controlled through carefully established and controlled conditions during the cell 
culturing, product processing and purification steps.[5]  
2?
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3The production and engineering of therapeutic mAbs was made possible by the 
groundbreaking hybridoma technology developed by Milstein and Köhler in 1975.[6] 
Hybridoma technique consists of first injecting a specific antigen into a mouse, and
procuring the antigen-specific plasma cells from the mouse's spleen. The isolated plasma 
cell is then fused with a cancerous immune cell for immortality.[7] This hybrid cell is
then cloned to produce many identical daughter clones which continuously produce the 
monoclonal antibody of interest. Initially, only murine (derived from only mouse) 
monoclonal antibodies were produced with this technology, for example ibritumomab 
tiuxetan and tositumomab.  As these murine antibodies triggered strong immune reactions 
in humans, especially on repeated administration, other mAb types were created through 
additional engineering and recombinant technology. Cetuximab and rituximab are 
examples of chimeric mAbs. Chimeric mAbs are constructed with VL and VH from 
murine sources and CH1, CH2, and CH3 from humans.[8] Further reduction of the murine 
content led to humanized mAbs, such as trastuzumab and alemtuzumab. Humanized 
mAbs are predominately derived from the human structure, with only the CDRs made up 
of murine origin. Ultimately, the production of fully human mAbs was made possible 
through two technologies, phage display and transgenic mice. The expectation, however, 
that the reduction and ultimately complete removal of murine components from mAbs 
would result in better tolerability and less or no immunogenic reactivity did only partially 
hold true, as immunogenicity of mAb products does seem affected by factors beyond the 
content of murine structures in the mAb molecule. 
???????????????????????????????
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The extent of mAb distribution relies upon the rates of extravasation in tissue and 
distribution in the interstitial space, antibody binding to the tissue components such as 
cell surfaces, and clearance from the tissue, including intracellular uptake and 
degradation. For a mAb’s extravasation can occur via three basic processes: passive 
diffusion, convective transport and transcytosis through vascular epithelial cells. Due to 
the physiochemical properties and large size of mAbs, passive diffusion does not play a 
significant role in the extravasation process. The main mechanism by which mAbs 
distribute from the blood into the tissue is through convective transport.[9] Convection is 
determined by the flux of fluid from the vascular space to the tissue, which is driven by 
the blood-tissue hydrostatic gradient, as well as by the sieving effect of the paracellular 
pores in the vascular epithelium.[9-11] The sieving effect is determined by the size, 
tortuosity and number of the pores, as well as the size, shape and charge of the mAb.[9, 
11] The principle behind convection is that the differential between hydrostatic and 
oncotic (colloid osmotic) pressures, coupled with the sieving effect, contributes to the net 
driving force for the extravasation of the mAb (??????????). Transcytosis through 
vascular epithelial cells, mediated via the FcRn receptor, may be another important route 
of extravasation for mAbs, especially in tissues where extravasation via convection is  
4?
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Reprinted with permission from Springer. Meibohm, B. (2013). "Pharmacokinetics and 
Pharmacodynamics of Peptide and Protein Therapeutics." Pharmaceutical Biotechnology: 
Fundamentals and Applications. D. J. A. Crommelin, R. D. Sindelar and B. Meibohm. 
New York, NY, Springer New York??101-132. 
5limited.[12] Several studies have shown a bidirectional transport of IgG from basolateral 
to apical and apical to basolateral directions.[13-16] This suggests that FcRn mediated 
transcytosis may also play a role in the distribution of mAbs from the central 
compartment out into tissue compartments. 
After extravasation, antibody distribution through the interstitial space relies upon
diffusion, convection and affinity to target antigens within the interstitial space or on cell 
surfaces in the tissues. In cases where there is no target antigen for the mAb to bind (such 
as in preclinical mouse studies with a human mAb that is not cross-reactive to the murine 
analogue of its target antigen) or the target is in the plasma, the distribution of the mAb is
expected to be limited. MAbs that have a target in the tissue compartment are expected to 
potentially have a greater volume of distribution. For endogenous and exogenous 
antibodies the tissue:blood concentration ratio is in the range of 0.1-0.5, i.e. mAb 
concentrations are substantially lower in the tissue interstitial fluid than in plasma.[9, 17] 
For brain tissue, the ratio is even in the range of 0.01 or lower.[18] In cases where the 
mAb binds with high affinity to extravascular sites with high binding capacity 
tissue:blood concentration ratios may be much higher.[9, 17, 19, 20] It is worth noting 
that in cases where the binding capacity of the target is limited, a nonlinear distribution 
could occur where the volume at steady state decreases with increasing plasma mAb 
concentrations.[21] 
Tissue distribution by large proteins, such as IgG molecules, is further hindered 
by the extracellular matrix. The interstitial space is filled with extracellular matrix, which 
has a gel like consistency with a net negative charge and is predominantly comprised of 
glycosaminoglycans (e.g., hyaluronic acid) and structural proteins such as collagen. 
There is a mutual exclusion between IgG molecules and the structural proteins of the 
extracellular matrix. The fraction of the extracellular matrix that is not available for 
distribution is expressed as the excluded volume (Ve).[22] It is dependent on the 
molecular weight and charge of the macromolecule and further limits the extravascular 
distribution for mAbs.[23]  The Ve for IgG molecules has been reported as ~50% in 
muscle and skin tissue.[24, 25] 
Distributive antibody removal from the interstitial space is dependent on the rate 
of antibody convection into the lymph. The process is the same as convection from the 
blood vessels into the interstitial tissue space, relying on pressure gradients, fluid flow 
rate (lymph flow rate), and sieving. The movement of the mAbs from the interstitial 
tissue space into the lymph is met with less resistance compared to extravasation due to 
the relatively large diameter of the lymph duct pores compared to the paracellular pores 
in vascular epithelium. Due to the vast differences in efficiency between convection into 
the interstitial space and out of it, unbound antibody concentrations are much lower in the 
interstitial space of tissues than in the vascular space. This concentration difference is 
more pronounced in tissues associated with tight junctions between endothelial cells as 
compared to tissues with leaky capillaries.?As a result, the volume of the central 
compartment Vc for most mAbs is in the range of 2-3 L, similar to the plasma water, and 
the overall volume of distribution at steady-state (Vss) is in the range of 8-20 L.[4] 
6Physiologically based pharmacokinetic models have been used to describe the 
process of distribution of an antibody through convection as a product of the lymph flow 
rate (L), which represents the hydrostatic gradient, and an efficiency term (1-ơ). The ơ is 
a reflection coefficient and represents the fraction of antibody sieved during the 
movement of blood through the pore and can have a value between 0 and 1. Reflection 
coefficients for large molecules, like mAbs, are assumed to be around 0.95 in tissues with 
continuous capillaries (tissues with tight junctions), such as connective tissue, skin and 
muscle.[26] The reflection coefficient in fenestrated capillaries and sinusoids (liver, 
spleen and bone marrow), which have leaky junctions, is in the range of 0.31 and 
0.42.[26] 
??????????????? ????
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Antibodies are eliminated by either excretion or catabolism. Unlike small 
molecules, mAbs are too large to be filtered by the kidneys and are not eliminated in the 
urine, except in pathologic conditions.[27] If low molecular weight antibody fragments 
are filtered they are usually reabsorbed and metabolized in the proximal tubule of the 
nephron.[28] Biliary excretion accounts for a very small amount of the elimination of IgG 
antibodies. Thus, IgG elimination occurs mostly through intracellular catabolism by 
lysosomal degradation to amino acids after uptake by either pinocytosis, a unspecific 
fluid phase endocytosis, or by a receptor-mediated endocytosis process.[29]  
Receptor-mediated endocytosis of IgG results from interaction of cell surface 
receptors with either the Fc domain or one of the Fab binding domains of the antibody. 
This binding event serves as trigger for the endocytotic internalization of the IgG 
molecule into a vesicle and subsequent lysosomal degradation.  If the binding event is 
facilitated though interaction of the complementary-determining region of the Fab 
fragments with the specific target epitope for the mAb, the endocytosis and elimination is 
called target-mediated drug disposition (TMDD).[30] The rate of elimination of a drug 
through TMDD is dependent on the expression of the target receptor (which is usually 
limited), the affinity of mAb for the receptor, the dose of the mAb, the rate of receptor-
therapeutic protein internalization, and rate of catabolism within the target cell. It is 
important to note that the antibodies cleared primarily by TMDD will have dose-
dependent nonlinear elimination. Due to the high binding specificity and affinity of the 
mAb for its target, TMDD is for many mAbs, with a membrane-standing target, a major 
route of elimination at low doses and concentrations. At higher doses and concentrations, 
especially therapeutic doses for mAbs intended to block a cell surface receptor, the 
TMDD elimination pathway is oftentimes saturated due to the limited availability of the 
target receptors, thereby resulting in a limited or no relevant contribution to overall 
clearance of the mAb. 
Receptor-mediated endocytosis of mAbs can also be facilitated through binding of 
the Fc domain to Fc-gamma-receptors (FcƴR) expressed on many immune cells 
including, monocytes, macrophages, myeloid progenitor and dendritic cells.[31] Similar 
to the TMDD process, binding of IgG to FcƴR triggers the endocytosis of the complex 
7and subsequent intracellular catabolism. Binding of immune complexes to FcƴR is an 
important pathway for immune signal processing.[32] Studies with FcƴR knockout 
animals suggest that FcƴR mediated elimination plays likely only a minor role (if any) for 
most mAbs.[33] For those mAbs, however, that form soluble immune complexes, 
mediate their pharmacology activity through effector functions such as ADCC, and/or 
have increased binding affinity to FcƴR, receptor-mediated endocytosis via FcƴR may 
constitute an additional elimination pathway that contributes to the over elimination of 
the mAb. This has for example recently been demonstrated for elotuzumab.[34] 
Pinocytosis is a relatively unspecific fluid-phase endocytosis by endothelial cells 
lining the blood vessels. Due to the large surface area of endothelial cells in the body 
(>1000 m2) the process efficiently eliminates IgG molecules from the body. Catabolic 
degradation of IgG following pinocytotic uptake is not limited to a specific organ but 
occurs throughout the body, particularly in those organs and tissues rich in capillary beds 
with endothelial cells. Thus, the skin, muscle and gastrointestinal tract are the major 
elimination organs for IgG molecules that do not undergo receptor-mediated elimination 
pathways.[35] 
Since the intracellular uptake via pinocytosis does not differentiate which proteins 
in the surrounding of a cell are taken up for degradation, a protective mechanism for IgG 
molecules is necessary to maintain their concentrations in the plasma. This salvage 
pathway is provided by the neonatal Fc-receptor (FcRn), also named the Brambell 
receptor.[36]??????????? illustrates the mechanism:[37] IgG is taken up into catabolic 
cells by fluid-phase endocytosis forming an endosome which includes FcRn. At 
physiologic pH FcRn has low affinity for IgG, but as the endosome is acidified the
affinity of FcRn increases and allows the IgG to attach via a specific binding site in the 
Fc domain. Once bound, the FcRn-IgG complex will be returned to the cell surface and 
release the IgG molecule from the binding once physiologic pH has been reached. 
Proteins in the endosomes that are not bound to FcRn and recycled undergo proteolytic 
degradation in the lysosome. The FcRn-mediated recycling of IgG molecules, including 
therapeutic mAbs, protects approximately two thirds of the IgG molecules taken into 
endosomes from catabolic degradation.[38] As a consequence, the elimination half-life 
for IgG1, IgG2 and IgG4 is approximately 18-21 days, which is substantially longer than 
the half-life of other proteins with similar molecular weight.[39] IgG3 molecules that 
have a substantially lower binding affinity to FcRn exhibit a half-life of 7 days. Besides 
serving as a salvage pathway, FcRn also facilitates transcytosis of mAbs in a variety of 
organs and tissues. 
The efficiency of the FcRn-mediated recycling was illustrated in FcRn knockout 
mice, for which IgG clearance increased by tenfold.[40] Similarly, increasing the binding 
affinity to FcRn through protein engineering could further reduce IgG clearance.[41]. 
Though efficient, there is a limit to the FcRn recycling capacity. At physiologic IgG 
concentrations of 12 mg/mL, IgG has a half-life of approximately 21 days. Introducing 
high concentrations of IgG, either exogenously as in the case of high-dose intravenous 
immunoglobulin (IVIG) therapy, or endogenously in conditions such as multiple 
myeloma, there will be an increase in IgG clearance and reduced half-life by saturating  
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9the FcRn recycling process.[42] Conversely, hypogammaglobulinemia would be 
expected to decrease the clearance and increase the half-life of therapeutic mAbs. 
Significant changes in FcRn recycling, however, are not achieved with therapeutic doses 
of mAbs, because most mAbs are given at dose less than 10 mg/kg, which would increase 
the overall amount of IgG in the body by only 1-2%.[43] 
?????????????????????????
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MAbs do not have an appreciable oral bioavailability due to their large size, 
limited membrane permeability and limited stability towards gastrointestinal protease 
activity. Therefore, intravenous infusion is the most common route of administration, 
followed by subcutaneous (SC) and intramuscular (IM) injection. SC is used for a 
majority of mAbs that are not given through the IV route. SC delivery of mAbs involves 
an absorption process from the site of injection that relies significantly on the convective 
transport of the mAb through the interstitial space into the lymphatic system, draining 
into the systemic circulation.  
Similar to the distribution processes for mAbs, uptake of IgG molecules after 
injection into the interstitial space of subcutaneous tissues is largely driven by convective 
transport with only minor contribution from distribution processes. Transcytosis of IgG 
via FcRn contributes also, though only minimally to subcutaneous absorption.[44] In line 
with other therapeutic mAbs for which the percentage of recovery in lymphatic versus 
blood vessels is increasing with increasing molecular weight,[45] mAb absorption after 
SC administration is nearly exclusively facilitated by the lymphatic system rather than the 
vascular system. Since the flow of lymph fluid in lymphatic vessels is very slow 
compared to the blood flow in capillary vessels, the resulting absorption process of mAbs 
into the systemic circulation after SC administration is also slow, with a corresponding 
slow increase in plasma concentration and delayed time of the maximum concentration 
(Tmax), ranging for mAbs from 1.7?13.5 days,[44] with frequent values of Tmax around 
6-8 days. A model-based analysis suggests that lymphatic flow rate is the only influential 
factor to Tmax.[44]  
Subcutaneously administered mAbs may undergo presystemic elimination. This is 
thought to be a combination effect of soluble peptidase activity in the interstitial space, 
endocytosis and subsequent lysosomal degradation in endothelial cells lining the 
lymphatic vessels with involvement of the FcRn recycling pathway, as well as interaction 
with phagocytic immune cells in the lymph nodes, whereby the latter two processes are 
assumed to be most prominent. The resulting reported bioavailability for SC administered 
mAbs ranges from 52 to 80%. [4, 44] The underlying degree of presystemic degradation 
has been suggested to be a function of lymphatic residence time and elimination rate 
during lymphatic transport.[44] 
A variety of factors have been shown to influence SC absorption and 
bioavailability of mAbs. The site of injection may play a factor in the rate and extent of 
absorption for mAbs.[46] This is due to the changes in pressure gradient in the interstitial 
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space at different sites of injection, as well as the amount of lymph movement near the 
sites of injection, that can also be modulated by activity/motion near the site of 
injection.[47] 
Product-specific factors that affect absorption are charge, size, formulation, and 
total dose given of the mAb.[48] The net charge of the IgG molecule changes the 
lymphatic uptake characteristics. Due to the slightly negative charge present in the 
interstitial space, the highest uptake is seen with negatively charged proteins, with 
positively charged molecules absorbed slower.[49] The SC bioavailability for rituximab 
was found to be inversely related to dose level, which might be attributed to saturation of 
the FcRn-mediated salvage pathway at the absorption site and the corresponding 
lymphatic vessels draining that area.[48] 
Species-specific characteristics which are important for absorption are skin 
morphology, catabolic capacity at injection site, blood flow at the site of injection, and 
FcRn receptor affinity.[50] All of these characteristics play a role in the absorption 
profile in each species, and make it difficult to scale a pharmacokinetic profile from one 
species to another.[46] For example, FcRn receptor affinity to human IgG varies across 
species, which needs to be considered in choosing an animal model for pharmacokinetic 
studies for mAbs. For example, human IgG1 has a ~2.5 fold higher binding affinity to 
mouse FcRn compared to human FcRn, resulting in a potential overemphasis of FcRn-
mediated absorption and disposition processes when human IgG1 mAbs are tested in 
mice compared to humans.[51]   
Subject specific characteristics which can have an effect on absorption are body 
weight, sex, age, activity level, disease state, respiratory rate, and blood pressure.[52] In 
humans, hypodermis thickness increases with body weight, decreases with age, and 
depends on gender, which has the potential of leading to different absorption behavior 
and variability.[53] The flow of lymph increases for example by 83% during 2 hours of 
exercise, which may have a substantial impact on the uptake of therapeutic proteins into 
the systemic circulation.[54] As a consequence of all these factors, there is substantial 
variability in the rate and extent of absorption between different mAbs and between 
different individuals for the same mAb.[4, 55] 
The outlined concepts have successfully been implemented in recent 
physiologically-based pharmacokinetic modeling attempts for mAb disposition after SC 
administration.[56] 
??????????????????????????????????????????????????????????? ????
?
?
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Charge is one of the major determinants of how a mAb interacts with the 
negatively charged components of the cell surface. Changes in charge have been shown 
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to change the pharmacokinetic behavior of mAbs in serum, interstitial space and 
tissue.[57] An increase in isoelectric point (pI) by greater than 1 unit through cationic 
modifications, for example, increased plasma clearance and resulted in a higher 
distribution into tissue.[58] MAbs with higher pI values had not only faster systemic 
clearance, but also lower subcutaneous bioavailability compared to antibodies with lower 
pI.[59] On the other hand, anionic modifications, causing a decrease in pI by 1-2 units, 
were shown to decrease plasma clearance and tissue accumulation.[60] Though not any 
small change in pI will have an effect on PK, pI changes above 1 unit in either direction 
are considered to result in appreciable differences in mAb pharmacokinetics.[61]  
?
??????????????????????
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Some of the pharmacodynamic effects of mAbs rely on immune mediated effector 
functions including ADCC and CDC. In CDC-mediated effector activity, the binding of
compliment C1q to a specific binding site on the Fc domain is critical in the initiation of 
the compliment cascade, which ultimately leads to lysis of the target cell.[62] In ADCC-
mediated effector activity, the Fc portion of the mAb binds to an Fcƴ receptor on an 
effector cell such as a monocyte, macrophage or natural killer cells, while the Fab 
domains bind to cell surface receptors on the target cell. This leads to the destruction of 
the target cell by either engulfing the cell through phagocytic activity by the immune cell 
or release of cytokines leading to cell death.[62] A critical component in a mAb’s ability 
to elicit ADCC or CDC is its affinity to FcƴR and C1q, respectively, which is modulated 
by carbohydrate (glycan) chains at the Asn297 amino acid in the CH2 domain of the Fc 
region (??????????).[63]  
The glycan chains attached at the Asn297 amino acid show substantial 
heterogeneity between and within mAb products. Several defined molecular species of a 
mAb with different glycan chains may coexist in the same mAb product.  The originally 
marketed form of trastuzumab (Herceptin®), for example, eight different isoforms with 
different glycan chains are contained at specific relative ratios in the marketed 
product.[64]  
Different glycan chains have been associated with differences in the 
pharmacodynamics and pharmacokinetics of mAb species. Afucosylation, i.e. the 
absence of the sugar fucose linked to N-acetylglucosamine (GlcNAc) glycan attached at 
the Asn297 of the Fc domain, for example, results in dramatically enhanced ADCC due 
to enhanced Fc-gamma-receptor IIIA (FcγRIIIa) binding affinity without any detectable 
change in CDC or antigen binding affinity. [65]  A combination of only the afucosylated 
forms of trastuzumab compared to the marketed trastuzumab product that contains 
fucosylated and non-fucosylated forms not only increased efficacy in an in vivo tumor 
model, but also reduced half-life from 13.1 to 10.1 days, likely due to the accelerated 
removal of trastuzumab molecules through the ADCC mechanism.[64] 
Other glycosylation patterns have also been shown to affect mAb 
pharmacokinetics: IgG that lacks galactose (G0% glycoforms) of IgG2 and potentially  
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IgG1 remains 20-40% longer in circulation in mice compared to other glycoforms. A 
potential explanation is a higher binding affinity of galactosylated forms to Fc?RI.[66] 
PK studies in Cynomolgus monkeys suggest that species of Fc fusion proteins with 
terminal N-acetylglucosamine are selectively cleared faster than species with other 
glycan structures.[67] The effect of terminal N-acetylglucosamine could be confirmed in 
humans.[68] Similarly, a three times faster clearance was noted for the high mannose 
glycans (Man5; Man8; Man9) compared to regular complex-fucosylated forms (FA2G1, 
FA2BG2S1), probably facilitated by the mannose receptor.[69] Overall, the alterations of 
clearance caused by varying glycosylation patterns are still being explored and have not 
been fully elucidated.[70] 
??????????????????????????????????????????????????????????? ????
?
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The pharmacokinetics of mAbs may be affected by functionally relevant genetic 
polymorphisms in genes encoding for proteins relevant for their distribution and 
elimination. The expression of one of the protein components of the heterodimeric 
neonatal Fc-receptor, FcRn, for example, is affected by a genetic variant in the FCGRT
gene encoding for it. The promoter region for FCGRT exhibits a 37-base pair variable 
number of tandem repeats (VNTR) polymorphism that affects the level of expression of 
FcRn. The most common VNTR3/VNTR3 genotype expresses 1.66-fold more FcRn 
transcript compared to the VNTR3/VNTR2 genotype.[71] As a consequence, patients 
with inflammatory bowel disease that where heterozygous exhibited 14% lower exposure 
for infliximab compared to patients homozygous for VNTR3, likely due to reduced 
salvage of IgG secondary to decreased FcRn expression, resulting in increased clearance 
and decreased systemic exposure of the mAb. A similar, but substantially more 
pronounced effect of 24% was observed for adalimumab, which may be explained by the 
fact that adalimumab is given by the SC route and infliximab by the IV route.[72] 
Reduced FcRn expression may have affected not only the clearance, buy also the 
bioavailability of adalimumab by its modulation of presystemic degradation. These 
observations are supported by studies in patients receiving intravenous immunoglobulin 
G (IVIG) [73], where the efficacy of treatment is higher in VNTR3 homozygotes.
Similar to FcRn, genetic variants relevant for the pharmacodynamics and 
potentially also pharmacokinetics of mAbs have also been described for Fc? receptors, 
particularly Fc?RIIIa. Clinical response for trastuzumab in HER2-overexpressing breast 
cancer patients was found to be significantly correlated with a genetic polymorphism in 
the gene encoding for Fc?RIIIa resulting in an exchange of valine (V) against 
phenylalanine (F) at position 158.  The amino acid exchange influences the affinity of 
IgG1 to the Fc? receptor, resulting in an increased binding affinity and improved 
mediation of ADCC for the V allele compared to the F allele. Consequently, patients with 
V/V genotype exhibited higher objective response rates and longer progression-free 
survival.[74]  Similar results were reported for cetuximab in colorectal cancer[75] and 
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rituximab in B-cell lymphoma.[76]  For infliximab, the effect of the Fc?RIIIa genotype 
was suggested to not only be limited to pharmacodynamic efficacy, but also to affect 
pharmacokinetics, with a reduced clearance for the F/F genotype.[77] These data suggest 
that Fc? polymorphisms may affect mAb disposition if ADCC is a major elimination 
pathway for a specific antibody drug, but may have little or no impact on exposure for 
those mAbs where ADCC is only a minor or not a relevant clearance pathway. 
????????????????????
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Proteolytic degradation, as the prime elimination pathway for mAbs, can be 
affected by a variety of disease states, including cancer, injury and chronic inflammatory 
conditions. Cancer-associated symptoms, in particular the progressive loss of weight and 
lean tissue, are manifestations of an ongoing chronic inflammatory response.[78] This
elevated inflammatory status results in a 50-70% higher whole body protein turnover rate 
in cancer patients compared to normal individuals.[79] This affects not only the 
catabolism of many endogenous proteins, including IgG molecules, but also exogenous 
proteins such as therapeutically used mAbs. As a consequence, nonspecific proteolytic 
clearance of mAbs is not constant among patients, but may differ substantially among 
patient groups with a different indication or disease severity based on the degree of 
differences in protein turnover secondary to differences in inflammatory status. This has 
for example been described for the pharmacokinetics of trastuzumab, where systemic 
exposure in patients with HER2-positive advanced gastric or gastro-esophageal junction 
cancer was 30-40% lower compared to patients with HER2-positive metastatic breast 
cancer.[80] Similarly, clearance for infliximab has been reported as on average 0.37-0.41 
L/day in Crohn’s disease and ulcerative colitis, but only 0.26-0.27 L/day in rheumatoid 
arthritis and ankylosing spondylitis.[81] 
In line with these observations, serum albumin concentrations have frequently 
been reported as an inversely correlated covariate for mAb clearance, where increased 
albumin levels are indicative of decreased IgG clearance.[4] Hypoalbuminemia is a well-
recognized marker of cachexia and elevated protein turnover secondary to chronic 
systemic inflammatory conditions, as observed in many cancer indications. The 
endogenous catabolic rate for albumin is highly correlated with the catabolic turnover of 
immunoglobulin G.[82] Thus increased protein turnover, as indicated by 
hypoalbuminemia, results in increased catabolic degradation of IgG molecules, and thus 
increased clearance and reduced systemic exposure of therapeutically administered 
mAbs. 
Similar to albumin, C-reactive protein (CRP) has also been identified as a 
predictor for mAb clearance. CRP levels correlate positively with mAb clearance, though 
CRP is a relatively unspecific indicator of systemic inflammation.[83] This correlation is 
usually not as strong as for albumin, as CRP is much more variable than serum albumin 
concentrations and is controlled by a larger variety of factors. 
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Being a function of the systemic inflammatory status, catabolic degradation of 
mAbs may not necessarily be constant within a specific patient but may change with 
time.  This may become relevant for patients undergoing long-term therapy with mAbs, 
for example in many cancer indications or chronic inflammatory conditions.  The time-
dependent change of endogenous protein turnover, and thus mAb clearance, may be 
produced by either the natural progression of the disease or by the pharmacodynamic and 
therapeutic effects of the mAb. 
If this process is taking place in a mAb therapy in cancer indications, then patients 
with the most pronounced therapeutic response to therapy should experience the largest 
reduction in mAb clearance over time. This is due to the reduction of the systemic 
inflammatory condition, which is in contrast to non-responders where little or no time-
dependent change in mAb clearance should occur. Recent observations for nivolumab 
and pembrolizumab seem to support this notion: patients experiencing partial or complete 
response under anti-cancer therapy with either of the mAbs exhibited the largest decrease 
in clearance over time, while patients with progressive disease showed the smallest time-
dependent change in clearance.[84] 
The time-dependent change in mAb clearance, as a function of response to 
therapy, poses substantial challenges in a reliable assessment of exposure-response 
relationships for mAbs, as exposure is in these cases is not an independent variable for 
predicting response. This is especially the case for posthoc analyses of exposure-response 
data from studies with only one dose level, as these studies may potentially be biased and 
misleading.[85] 
???????????????
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Administration of therapeutic mAbs to patients may trigger an immune response, 
leading to the formation of anti-drug antibodies (ADA). Immunogenicity is the ability of 
a particular substance, such as a mAb, to cause an immune response.  The immunogenic 
potential of mAbs is related to a variety of factors, including the fraction of nonhuman 
sequence in the protein molecule, the route of administration, as well as dose and 
duration of therapy. Immunogenicity increases as the fraction of nonhuman sequence 
increases, with fully rodent mAbs being more immunogenic than chimeric mAbs, which 
are more immunogenic than humanized mAbs, which are generally more immunogenic 
than ‘fully’ human mAbs.[86] Nevertheless, even mAbs with a structure that is 
completely analogous to a human IgG molecule may exhibit immunogenicity. The degree 
of the formation of aggregates and the occurrence of T-cell epitopes have been discussed 
as potential determinants.[87] Route of administration also affects the probability of an 
immune response: SC administration oftentimes elicits a higher likelihood compared to 
intramuscular or IV administration, potentially secondary to aggregate formation at the 
injection site.[88] The dose of a mAb interestingly may have an inverse relationship to 
immunogenicity. It has been observed that low doses of a mAb often elicits a greater 
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immune response compared to a high dose of the same mAb.[89]  The mechanistic basis 
for this observation remains elusive, although it may be speculated that ADA formed by a 
weak immunogenic response may be consumed by high mAb concentrations in high dose 
groups, thereby masking the immunogenic effect without major influence on mAb 
exposure. The duration of therapy also has an effect on immune response. As duration of 
treatment lengthens the chances to elicit an immune response also increases.[90] The 
binding affinity of ADA will also mature/increase over time as more mAb is 
introduced.[91] As binding affinity increases, so will the potential of a decrease in the 
therapeutic mAb concentration and clinical effect. Predisposition to form an immune 
response has more recently also been linked to patient genotype, for example certain 
human leukocyte antigen (HLA) haplotypes.[86] 
Immunogenicity resulting in ADA formation is usually a polyclonal response, 
with multiple ADA species concurrently available and interindividual differences from 
patient to patient. The formed ADA can either be neutralizing antibodies or non-
neutralizing antibodies. Neutralizing ADA obliterate the effect of the mAb by binding to 
complementarity determining regions, i.e. their active sites. The level of neutralization is 
dependent on the titer of ADA. Neutralizing antibodies that are at low titers may not 
show a clinical effect, but at high titers there is a greater potential to see a decrease in 
clinical efficacy.[88] Non-neutralizing ADA do not interfere with the mAb’s antigen 
binding capacity. Independent of whether ADA are neutralizing or non-neutralizing, 
ADA formation frequently has an effect on the pharmacokinetics and systemic exposure 
of the affected mAb, although not all ADA results in a change in the mAb’s 
pharmacokinetic behavior. If there is an effect on pharmacokinetics, it is usually a 
dramatic increase in the elimination of the affected mAb, resulting in a substantially 
reduced or no appreciable systemic exposure of the mAb.[92] The mechanistic basis for 
this increased clearance is the formation of circulating ADA-mAb immune complexes 
that are large enough to trigger uptake and lysosomal degradation by the 
reticuloendothelial system, mediated for example via binding of the Fc domain for Fc?
receptor, primarily Fc?RIIA on platelets, and subsequent internalization by circulating 
phagocytes.[93]. Thus, ADA-mAb complex formation constitutes an additional clearance 
pathway for the affected mAb that may substantially contribute to is disposition and 
removal from the systemic circulation (??????????).[92] 
????????? ???????????????
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The pharmacokinetics of most therapeutically used mAbs have been described by 
compartmental modeling approaches, using the classic two-compartment model with 
reversible drug transfer between a central and a peripheral compartment. Drug 
elimination is usually described by a linear, first-order elimination pathway from the 
central compartment, that may be complemented by a parallel, nonlinear elimination 
pathway that exhibits Michealis-Menten-style kinetics, with a defined maximum 
elimination rate (Vmax) and a Michealis-Menten constant (km) defining the 
concentration at which the elimination pathway is half saturated.[4, 55] The 
pharmacokinetics of mAbs that undergo TMDD have also been described by  
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Multiple clearance pathways affecting the pharmacokinetics of a monoclonal antibody 
(mAb). Depicted is a typical two-compartment pharmacokinetic model for a mAb with 
administration of a dose (D) that may undergo pre-systemic degradation (degradation rate 
constant [kdeg]), concentrations of the MAb in the central (Ab1) and peripheral (Ab2)
compartment, and interdepartmental clearance (Q). The pharmacokinetic model includes 
two linear clearance pathways representative of unspecific proteolytic degradation, one 
from the central compartment (CL1) and one from the peripheral compartment (CL2), as 
well as recycling through the neonatal Fc-receptor (FcRn)-mediated salvage pathway 
(recycling rate constant [Krmr]). Added to these clearance pathways is, on the right-hand 
side, a target-mediated disposition pathway that constitutes interaction of the MAb with 
its pharmacologic target receptor, which is in a homeostatic equilibrium of synthesis and 
degradation (rate constants ksyn and kdeg). The dynamic equilibrium for the formation of 
the resulting MAb–receptor complex (Ab–R) is determined through the association rate 
constant kon and the dissociation rate constant koff. The formation of Ab–R not only elicits 
the pharmacologic effect but also triggers degradation of the complex. Thus, target 
binding and subsequent Ab–R degradation constitute an additional clearance pathway for 
the mAb (CL3). The left-hand side of the graphic depicts the effect of an immune 
response to the MAb resulting in anti-drug antibody (ADA) formation. Again, the 
circulating concentration of the ADA is determined by a homeostatic equilibrium 
between its formation rate (kformation) and a catabolic turnover process (rate constant 
[kcat]). The ADA response results in the formation of immune complexes with the drug 
(ADA–Ab), dependent on the dissociation constant Kd. Dependent on the size and 
structure of the immune complexes, endogenous elimination pathways through the 
reticuloendothelial system may be triggered, most likely via Fc?-mediated endocytosis. 
Thus, immune complex formation and subsequent degradation may constitute an 
additional clearance pathway (CL4) for MAbs (modified from Chirmule at al, [92];
reproduced with permission of Springer) 
Reprinted with permission from Springer. Chirmule, N., et al. (2012). "Immunogenicity 
to Therapeutic Proteins: Impact on PK/PD and Efficacy." AAPS J ??(2): 296-302.
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permutations of the target-mediated drug disposition (TMDD) model. This model 
includes binding parameters for the mAb-target interaction as well as internalization rate 
for the mAb-target complex. While the full TMDD model has only been applied in few 
situations, largely due to the limited availability of concentration data beyond free or total 
mAb concentration, (e.g. target concentration, mAb-target complex concentrations) as 
well as the largely different time scales of the kinetic processes involved in the TMDD 
model (fraction of seconds for complex association rates versus days for elimination 
rates), simplifications and approximations of the full TMDD model have been widely 
applied. A comprehensive review on TMDD model variations has recently been reported 
in this journal.[94] 
In order to expand mAb modeling from not only describing plasma 
pharmacokinetics, but also tissue concentration-time profiles, as well as to facilitate a 
more mechanistic understanding of the impact of drug disposition processes of mAbs 
such as TMDD, convective extravasation, FcRn recycling, and proteolytic degradation, 
physiologically-based pharmacokinetic (PBPK) models have more recently been applied 
to characterize the complex disposition kinetics of therapeutically used mAbs.[95]  A
recent example for a full PBPK model includes 16 tissue compartments, each further 
divided into vascular, endosomal, interstitial and cellular sub-compartments, as well as 
physiological parameters for four species (mouse, rat, monkey and human), different 
vascular reflection coefficients for different tissues, use of an association and dissociation 
constants between mAb and FcRn, degradation rates for FcRn unbound mAb and use of 
pinocytosis clearance.[96]  
Minimal PBPK modeling can be seen as a middle ground between classical 
compartmental modeling and full PBPK modeling that allows for the incorporation of 
mechanistic key element in drug disposition without the need for extensive collections of 
estimated physiologic and theoretical parameters. In a recent minimal PBPK model, the 
compartmental complexity was reduced to two groups of tissues, the leaky and tight 
distribution volumes according to their vascular endothelium structure.[26] These kind of 
reductionist modeling approaches still allow consideration of many mechanistic and 
conceptual features of mAb drug disposition, but at the same time are not dependent on 
the assumptions of model parameters that cannot reliably be measured, accessed or 
estimated.  
???????????????????????
?
Although there is substantial heterogeneity in drug disposition and 
pharmacokinetics of mAbs, particularly if saturable distribution and elimination 
processes are involved, many of the therapeutically used mAbs exhibit similar 
pharmacokinetic behavior that is analogous to endogenous IgG molecules. Population 
estimates of the volumes of distribution in the central (Vc) and peripheral (Vp)
compartments are typically small, with median (range) values of 3.1 (2.4–5.5) L and 2.8 
(1.3–6.8) L, respectively, reflecting the limited ability of mAbs as large protein molecules 
to leave the vascular space.[4] The estimated between-subject variability in the Vc was 
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usually moderate, with a median coefficient of variation of 26%.[4] Much more limited 
information is available on the between-subject variability in other distribution-related 
parameters such as the Vp and intercompartmental clearance. The clearance of mAbs 
with linear elimination characteristics or at concentrations when target-mediated drug 
disposition processes are saturated typically ranged from 0.2 to 0.5 L/day, which is 
relatively close to the estimated clearance of endogenous IgG of 0.21L/day. The between-
subject variability in clearance was moderate with a median coefficient of variation of 
33%, ranging from 20 to 59%.[4] These values, however, may further be modulated by 
the various product- and patient-specific factors as outlined earlier in this chapter. 
???????????
?
MAbs are a unique class of therapeutics that exhibit pharmacokinetic behavior 
determined and controlled by the specific mechanisms and processes involved in their 
disposition. Although there are substantial differences in the pharmacokinetics of 
individual mAbs, their general behavior can still be considered a class property as it is
driven by and similar to their endogenous counterpart IgG. The mAb pharmacokinetic 
properties, however, can be further modulated by the various factors outlined in this 
chapter. 
????????????????????????????????????????????????????????????????????????????
??????????????????????????????????? ???????? ??????????
Pharmacokinetic-pharmacodynamic (PKPD) modeling and simulation is used 
today as a method of improving decision making in preclinical trials, early stage clinical 
trials and in late stage clinical trials during drug development. PKPD modeling is 
recognized as the most rational method for choosing first-in-human dosing, especially in 
the realm of therapeutic antibodies. 
PKPD modeling of therapeutic antibodies is challenging and requires knowledge 
of mechanisms unique to therapeutic antibodies. Therapeutic antibodies often have a site 
of action outside of the central compartment. These antibodies will require accurate 
prediction of not only plasma concentration, but also tissue concentration, since plasma
concentration may not accurately predict concentration at the site of action. In order to 
predict tissue concentrations, knowledge of TMDD, convection, FcRn recycling and 
proteolysis must be estimated using nontraditional approaches. Nontraditional approaches 
are required due to therapeutic antibodies’ nonlinear plasma pharmacokinetics, which are 
difficult to model using the traditional allometric scaling methods and mammillary-type 
compartmental models.[95, 97, 98] It is physiologically based pharmacokinetic (PBPK) 
models that are gaining recognition as an acceptable and realistic method of estimating 
drug pharmacokinetics compared to empirical compartmental models.[99] 
There have been several PBPK models made for therapeutic proteins, each 
improving or adding to the next. One of the more recent PBPK models was developed by 
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Shah and Betts,[96] and comprised a full PBPK model which improved upon the 
platform PBPK models published previously.[100, 101] The authors added more tissue 
compartments, four more species, up-to-date physiological parameter estimates, a more 
mechanistically detailed tissue compartment, different vascular reflection coefficients for 
different tissues, use of association and dissociation constants between mAb and FcRn, a
first-order degradation rate constant for mAb not bound to FcRn, the use of a pinocytosis 
clearance.[96] 
This PBPK model includes 16 tissue compartments. Each of the tissue 
compartments is further divided into vascular, endosomal, interstitial and cellular sub-
compartments.[96] The model structure and equations will stay the same for each of the 
species considered for this PBPK model (mouse, rat, monkey and human),[96] but he 
physiological parameters changed for each species. The Shah and Betts model
characterizes mAb pharmacokinetics in both the plasma and tissue. By taking into 
consideration important pharmacokinetic features of mAbs, such as FcRn disposition, 
target-mediated drug disposition and correlation between the isoelectric value pI and 
plasma and tissue distribution this model was able to reasonably estimate both plasma 
and tissue concentrations across the multiple species.[96] Antibody drug conjugates 
could potentially also be evaluated by the model by adjusting the reflection 
coefficients.[96] However, it is important to recognize that these PBPK models are not as 
developed and tested as their counterparts in small molecules. So as more data come out 
about mechanisms of therapeutic antibody distribution, elimination and absorption, it is 
important to adapt these models to take into account these newly discovered mechanisms. 
Minimal PBPK modeling is another technique that can be used to describe the 
kinetics of a therapeutic protein when only plasma concentration data is available. 
Minimal PBPK models provide a simpler way to estimate plasma and tissue drug 
concentration and may act as a preliminary model to build upon when developing a full
PBPK model. In a recent publication, Cao and Balthasar adapted a previously developed 
full PBPK model to reflect only certain significant PK characteristics of the mAbs 
evaluated.[26, 102] Their model allows the obtaining of a system average estimate of 
drug concentrations instead of a tissue specific estimation provided by the full PBPK 
model. The minimal PBPK model focused on convection mediated by transcapillary 
escape rate (TER) as the means of mAb distribution into the extravascular space. This 
assumption was based on several studies that observed convection being the primary 
means for mAb distributing out into the extravascular space.[9, 10, 103] The minimal 
PBPK model also made the assumption that endothelial endosomes do not play a 
significant role in the distribution of this therapeutic antibody.[26] The structure of the 
minimal PBPK model is shown in ??????????. 
This minimal PBPK model divides the tissues into two groups, the leaky and tight 
volumes, according to their vascular endothelium structure.[26] This will help to estimate 
the concentration of drug in each tissue volume and gives an approximate average total 
drug in tissues. A major advantage of this approach is that it requires less 
parameterization, which allows for better parameter identifiability compared to the full 
PBPK model. 
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???????????? ????????????? ?????
In this model, drug enters the plasma compartment via intravenous injection. 
Vp represents the plasma volume. Vtight and Vleaky are volumes of interstitial fluid in
tissues that have continuous and discontinuous or fenestrated capillaries. Vlymph is lymph 
volume, assumed equal to blood volume. The L is total lymph flow equal to the sum 
of L1 and L2, the lymph flow for Vtight and Vleaky. The σ1 and σ2 are vascular reflection 
coefficients for Vtight and Vleaky. The σL is the lymphatic capillary reflection coefficient. 
The CLi and CLp are mAb clearances from the interstitial fluid and plasma. [26] 
?
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?????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????? ???????????????????
Regardless of the type of modeling approach used, the prediction of 
immunogenicity’s effect on the concentration-effect profile for a therapeutic antibody in 
the preclinical and clinical setting is difficult. This difficulty in prediction stems from the 
range of PK and PD responses that can occur, along with the variable effects on the 
bioanalysis.  
The bioanalytical methods used to evaluate the therapeutic antibody concentration 
are sensitive to ADA formation. ADA can directly interfere with the bioanalytical 
method in place. This interference of ADA is typically evaluated during the pre-study 
method development and compensated for, although these pre-study positive controls 
may not represent the gamut of host-specific polyclonal ADA responses to a therapeutic 
antibody encountered in clinical studies.[104] There is also the limitation of quantifying 
the concentration of ADA with our current technologies. In the absence of any ADA 
standard reagents, assays are limited to semi-quantitative assessments. The semi- 
quantitative values which are derived can vary depending on the assay used and each 
individual’s variable immune reaction, leading to a value that isn’t representative of a 
consistent in vivo response.[104] Therefore, the understanding of ADA’s highly variable 
effect on the PK of a therapeutic protein and the subsequent prediction of ADA’s effect 
from the preclinical studies may have limitations with the currently available 
bioanalytical technologies. 
The mechanism by which each the of the anti-drug antibodies affects the PK of a 
therapeutic protein is not well understood, and because of the polyclonal nature of the 
ADA response, a reliable approach to determining ADA affinity has proven difficult. 
From a PK aspect, ADA formation can cause an increase in the clearance,  or a sustaining 
effect on the concentration of the therapeutic protein.[92] The hypothesis of the 
mechanism behind ADA’s effect on the therapeutic protein’s clearance centers on the 
size of the ADA-protein therapeutic immune complex that is formed, as well as the 
number of antigenic sites on the therapeutic protein.[92, 105] Larger immune complexes 
tend to be cleared more readily, increasing the clearance of the therapeutic antibody, 
while smaller immune complexes may not be recognized by phagocytic cells, and 
therefore are not cleared by the reticuloendothelial system.[92] The number of antigenic 
sites hypothesis may be correlated with the size of the immune complexes, as when 
endogenous ADA are only directed against 1 or 2 sites on the therapeutic protein one 
may see a half-life similar to that of IgG, but if anti-drug antibodies are directed against 
three or more sites, the resulting immune complex will be rapidly cleared and the affected 
therapeutic protein will experience an increase in clearance.  
The pharmacodynamic effects of ADAs against a therapeutic protein are also 
variable. Each of the polyclonal ADA formed can have one of two effects on the 
therapeutic protein depending on where it binds on the molecule, the ADA titer and its 
binding affinity: (1) A neutralizing effect on therapeutic proteins activity, or (2) a non- 
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neutralizing effect on activity.[92] Neutralization of the therapeutic protein’s activity 
usually occurs if the ADA binds to the active site of the molecule, for example the 
complementarity-determining regions of a monoclonal antibody. If the ADA neutralizes 
the effect of the therapeutic protein, the level of neutralization is dependent on the titer of 
ADA. Neutralizing antibodies that are at low titers may not show a clinical effect, but at 
high titers there is a greater potential to see a decrease in clinical activity of the affected 
therapeutic protein.[88] The binding affinity of ADA may potentially also mature and 
increase over time as more therapeutic protein is introduced into the organism.[91] As
binding affinity increases, so will the potential of clinically relevant effect on the PK and 
PD of the therapeutic protein. 
Though there is a current lack of knowledge behind the mechanisms of ADA 
formation and effect on the PK and PD of a therapeutic protein, including mAbs, several 
modeling approaches have been published that try to help quantitatively assess ADA 
response.[106-108] The model proposed by Chen et al. may act as a base model.[106] It
is useful for situation when therapeutic protein concentrations change due to ADA 
formation. This PK/ADA model is much similar to a PKPD models. It hypothesizes that 
as ADA affinity matures, a change in the pharmacokinetic profile will be observed. The 
affinity maturation of the polyclonal ADA response is driven by cumulative dosing, in a 
manner similar to the effect of immunizations. This model can generate estimates of 
maximum ADA response, sensitivity to drug dose, affinity maturation, time lag required 
to observe ADA response, and elimination rate for the ADA-drug complex.[106] 
Although the model is used only to evaluate the drug-ADA interaction, it is flexible 
enough to be added into established TMDD models and/or full or simplified PBPK 
models.  However, the major limitation of this model is that it is only hypothetical until 
experimental validation, which is currently not possible due to technological limitations. 
As it stands, this model makes many assumptions about the immune system’s potential to 
react to a therapeutic protein, as well as how the reaction will affect the protein 
therapeutic’s concentration, which both can be highly variable. Therefore, until a better 
understanding on ADA formation and its effect on a therapeutic protein has been 
established, this model can be used as a hypothesis generating approach looking at the 
dynamics of ADA development and its effect on therapeutic protein concentrations.
Another approach to modeling ADA’s effect on mAb concentrations was 
proposed by Edlund el al.[107] The method applied tested the influence of anti-
infliximab antibodies on the clearance of infliximab, using the anti-infliximab ADA 
status or measurements as a covariate. Three mathematical methods were applied to 
incorporating the ADA covariate into clearance. The first method modeled the ADA-
clearance covariate relationship as a fractional change in clearance using anti-infliximab 
ADA information as a binary covariate on the patient level, with a patient being 
considered anti-infliximab positive if he/she exhibited equal to or greater than one sample 
with quantifiable anti-infliximab ADA.[107] The second method modeled the ADA-
clearance covariate relationship as a fractional change of clearance using anti-infliximab 
ADA information as a binary covariate at each sample time point, which gives it a time
varying aspect compared to the first method.[107] The third method modeled the ADA-
clearance covariate relationship with anti-infliximab ADA concentration included as a 
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continuous covariate with a linear relationship to clearance.[107] Each method was 
applied and all three lead to a better fit of the data, with the third covariate method 
leading to the best fit of the three.  
Perez-Ruixo el al. approached modeling ADA’s effect on mAb concentrations
using two other methods which avoided using ADA as a status variable, whether it be 
binary or continuous.[108] The novel methods were applied to data and a model which 
had been previously published on AMG 317.[109] The first method investigated by
Perez-Ruixo et al. involved implementing inter-occasion variability on the 
pharmacokinetic parameters of the model that played a part in clearance and could 
potentially be impacted by immunogenicity. This method allowed them to generate 
estimates of the post hoc model parameters that were dynamically estimated overtime 
according to the pharmacokinetic data observed at various specified occasions.[108] If 
the parameters changed and were influenced by ADA presence, they could be correlated 
with immunogenicity status as a time-dependent covariate and studied graphically, 
allowing for the effect of immunogenicity on AMG 317 pharmacokinetics to be 
determined.[108] The other approach used by Perex-Ruixo et al. involved developing a
population pharmacokinetic model using early data free of ADA interference. This model 
was then used to predict later drug concentrations. The predicted concentrations were 
then compared with the observed concentrations, and if a significant difference was seen 
between the predicted concentrations and the observed concentrations, immunogenicity 
could be confirmed.[108] Once immunogenicity was confirmed, the magnitude of that 
difference between the predicted and observed concentrations would quantify ADA’s
effect.[108]  
In conclusion, all of these modeling approaches aid in identifying the effect of 
immunogenicity on mAb concentration over time. However, it is important to understand 
that an ADA response and subsequent effect is dependent on different characteristics 
related to the mAb itself, as well as aspects related to the treatment protocol, and that the
data can be imperfect due to limitations in bioanalytical assays. All of these variables 
need to be taken into account when analyzing and modeling immunogenicity’s effect on 
mAb pharmacokinetics. 
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????????????? ???????? ??????????
Dynamic changes in biological processes are always present when researching 
and understanding new medications and pharmacotherapeutic approaches. Currently, 
preclinical pharmacokinetic and toxicological research with protein therapeutics is 
hampered by anti-drug antibody (ADA) formation against the therapeutic monoclonal 
antibodies (mAb), without a methodology to prevent or account for the immunogenicity 
and its dynamic and variable effect on the mAb pharmacokinetics. There is also a void in 
our current knowledge on the developmental changes in transport proteins, such as 
MRP2, and the dynamic changes in the pharmacokinetics of substrate medications due to 
modulation of transport protein expression. I therefore explored in this dissertation new 
immunomodulation treatment modalities to limit or prevent immunogenicity and new 
modeling and simulation based analysis strategies to account for immunogenicity and 
transport protein ontogeny and their variable and dynamic effect on drug exposure.  
?
??????????? ???
Immunogenicity can often alter the levels of therapeutic mAbs in preclinical 
animal studies performed during early drug development.  Fully human and humanized 
mAbs are frequently antigenic to rodents and nonhuman primates, which may result in 
reduced systemic exposure of the protein via immune-mediated clearance.[92] High 
immunogenicity has been addressed in the past by concomitant immunosuppression, such 
as co-administration of methotrexate with enzyme replacement therapy, and 
tacrolimus/sirolimus combination treatment for prophylaxis against organ transplant 
rejection.  I hypothesized that the use of such immune suppressants will mitigate an ADA 
response to a fully-humanized mAb in preclinical animal studies. 
In Aim 1 (Chapter 4) I tested this hypothesis by identifying regimens that initiate 
immune tolerance towards therapeutics that would otherwise be immunogenic in animals. 
By identifying immunomodulatory treatment modalities, I could provide an approach to 
mitigate immunogenicity in preclinical species. Such preconditioning can facilitate 
preclinical drug development of human therapeutics that are antigenic to animals but not 
necessarily to humans.   
?
??????????? ???
ADA formation during a preclinical study typically leads to an increase in 
clearance of the affected therapeutic mAb. The increase in clearance caused by ADA can 
be highly variable due to the unique and polyclonal nature of each animal’s response to 
an antigenic therapeutic mAb. Variability in physiologic processes and its dynamic effect 
on the exposure to the therapeutic can be captured through mathematical modeling and 
simulation approaches.[110] Therefore, I hypothesized that by using pharmacometric 
modeling and simulation I would be able to account for the variability seen in mAb 
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clearance and relate the observed changes in mAb exposure to the time-course and 
magnitude of the observed ADA formation.  
In Aim 2 (Chapter 5), I test this hypothesis by applying a PK-ADA modeling 
approach to analyze data acquired from the study performed in Aim 1 (Chapter 4). This 
methodology can aid in the development of appropriately powered toxicology studies, 
and a better understanding of the dynamic processes related to ADA formation and its 
impact on the exposure of the affected mAb. 
?
??????????? ???
Multidrug resistance protein 2 (MRP2) represents a major hepatic transporter 
whose expression is dynamic throughout childhood development. MRP2 plays a role in 
the biliary excretion of various organic anions and cations along with glutathione-, 
glucuronate-, or sulfate-conjugates of several drug substrates. To date, there has been a 
lack of studies that have evaluated the ontogeny of MRP2 and the effect it has on the 
disposition of its drug substrates. My hypothesis was that through a systems 
pharmacology modeling approach, I can account for the dynamic changes in MRP2 
expression during human development from early childhood to adulthood and its effect 
on the pharmacokinetics of drug substrates by integrating data from ex vivo studies, 
preclinical in vivo studies and clinical studies into a mathematical modeling framework.   
Therefore, in Aim 3 (Chapter 6) I evaluated the effect the ontogeny of MRP2 has 
on the pharmacokinetics of ceftriaxone to explore methods to better understand the 
contribution of a transport protein to the disposition of its substrates throughout 
childhood development. In order to accomplish my aim, a systems pharmacology 
modeling approach was used to understand MRP2’s contribution to the pharmacokinetics 
of ceftriaxone, and then to model these changes in the pharmacokinetics of ceftriaxone 
secondary to the ontogeny of MRP2 expression. This approach was explored to aid in the 
development of a platform with which to evaluate transporter ontogeny effects on 
therapeutic drug exposure.
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????????????? ???????????????????????????????????????????
???????????? ???????????????????????? ??????????????? ??
??????????????????????
?????????????
?
Immunogenicity can often alter the levels of therapeutic proteins (TP) in 
preclinical animal studies.  Humanized biologics are frequently antigenic to rodents and 
nonhuman primates, which may result in reduced systemic exposure of the protein via 
immune-mediated clearance [92].  When complexed with anti-drug antibodies (ADA) or 
complement, TP are cleared rapidly from circulation by antigen presenting cells via the
reticuloendothelial system [111].  ADA in animals may thus hinder more effective 
determination of dosing regimens in first-in-human drug trials [112, 113].  Numerous 
guidelines suggest that the few animals that do not develop ADA in response to cross-
species biotherapeutics may provide a more accurate picture of drug pharmacokinetics 
(PK) in subsequent human trials [114-116]. 
Several approaches have been used during preclinical development to circumvent 
the impact of ADA.  One such strategy includes dosing with high amounts of therapeutic 
protein so that sufficient amounts of drug remain in circulation despite immune 
clearance.  Alternatively, large numbers of animals per cohort could be utilized with the 
assumption that a few animals would be ADA-negative or display low ADA magnitudes.  
Recent approaches include the uses of humanized transgenic mice that have been 
tolerized to TP (e.g interferon, Factor VIII and human HLA transgenics) [117, 118], and 
xenograft models designed to mimic a human immune system (e.g. immunodeficient 
NOD-SCID IL2Rγ-/- or Rag2-/-γc-/- mice) [119].  However, these models are labor 
intensive to breed, cost prohibitive, and might not comprehensively represent the 
diversity of HLA alleles present in humans.  Therapeutic plasmapheresis, wherein plasma 
is reinfused after filtering out autoantibodies and antibody-antigen complexes, is yet 
another technically difficult method of mitigating ADA effects in animals [120]. 
  
In the clinic, approaches for minimizing immunogenicity risk have been 
successfully studied and implemented.   For enzyme-replacement therapy (ERT), 
immunogenicity has been addressed by concomitant immune suppressive regimens such 
as methotrexate [121, 122].  For non-enzyme based therapeutic proteins like fully human 
monoclonal antibodies, recombinant proteins with endogenous counterparts, fusion 
proteins, and novel modalities such as bispecific- and drug-conjugated antibodies, 
however, the use of immune suppressive regimens has not been evaluated.   
*This chapter adapted with permission. Ryman, J., et al., Immune Suppression During 
Preclinical Drug Development Mitigates Immunogenicity-Mediated Impact on 
Therapeutic Exposure. AAPS J, 2017. 
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In an effort to reduce the effect of ADA formation in preclinical studies, we 
focused on identifying regimens that initiate immune tolerance towards therapeutics that 
would otherwise be immunogenic in animals. The data generated in this study 
demonstrate that three cycles of methotrexate, as well as weekly doses of tacrolimus plus 
sirolimus induction, can be effective in reducing anti-drug antibody response after the 
rats were administered a fully human IgG2 based mAb once weekly for four weeks. 
????????
?
?
??????????
?
A highly purified, investigational fully human, IgG2 monoclonal antibody 
(referred to as mAb1) without endogenous target in rodents produced by Amgen Inc. 
(Thousand Oaks, CA) was used as the model TP in this study.  The purified stock mAb1 
solution (71.8 mg/mL) was stored at -80 °C, protected from light, thawed and stored at 4 
°C prior to use.  The following immune suppressive agents were purchased commercially 
as aqueous solutions for injection or oral administration: tacrolimus, a calcineurin 
inhibitor (Astellas, Deerfield, IL); sirolimus/rapamycin, an mTOR inhibitor (Wyeth 
Pharmaceuticals Inc., Philadelphia, PA); and methotrexate, an anti-metabolite (APP 
Pharmaceuticals, LLC, Schaumburg, IL). 
????????
?
Fifty-four male Sprague Dawley® rats (Strain: Crl: CD(SD)) were obtained 
(Harlan Laboratories Inc., Indianapolis, IN) at 6 weeks of age.  Once the animals were 8 
weeks of age and exceeded 300 grams, mAb1 was dosed weekly for 4 weeks.  The 
animals were sacrificed after 4 weeks (low- and moderate mAb1 dosages) or 11 weeks 
(high mAb1 dosage).  All animal experimentation was initiated after prior approval by 
the Institutional Animal Care and Use Committee (IACUC) of the University of 
Tennessee Health Science Center and performed in accordance with the USDA Animal 
Welfare Act: 9 CFR Parts 1, 2, and 3 [123] and the conditions specified in the Guide for 
Care and Use of Laboratory Animals [124].  
???????????????????????????
?
Rats were randomly assigned to one of 3 treatment groups (n=18 per group), 
which were further divided into 3 mAb1 dosage subgroups (n=6 per subgroup).  mAb1 
was administered every 7 days for 4 weeks via subcutaneous injection (??????????) at the 
back of the neck with injection sites being rotated between three locations: left, center, 
and right.  Methotrexate (Mtx) was administered as an intraperitoneal injection and 
tacrolimus (Tac) as a subcutaneous injection at a site separate from mAb1.  Sirolimus 
(Sir) was administered through oral gavage.  Animals in the control group received mAb1 
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?
???????????? ?????????????????????????????????? ????????????? ??????????????
????????????????????????????????????
The experimental plan for dosing of mAb1 alone (control group), mAb1 with tacrolimus 
and sirolimus (tacrolimus/sirolimus group), and mAb1 with methotrexate (methotrexate 
group) across 4 weeks is provided.  Each group had 18 animals per group that were 
subdivided into three subgroups with different mAb1 doses (0.01, 50 and 300 mg/kg with 
6 animals per dose group).  Immune suppression dosing regimens are also provided. 
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alone at low (0.01 mg/kg), moderate (50 mg/kg), or high (300 mg/kg) dosages without 
immune suppression.  The first immune suppression group, mAb1+Tac/Sir, was treated 
likewise with mAb1 plus sirolimus (6 mg/kg) at day 1 and tacrolimus (2 mg/kg) on days 
8, 15, and 22.  The treatment regimens were derived from previously tested protocols 
[125, 126].  In the second immune suppression group, mAb1+Mtx, animals received 
three intraperitoneal injections of methotrexate upon 0, 24, and 48 hours post initial 
mAb1 treatment.  This regimen for preconditioning of animals with methotrexate was 
selected for its proven success in inducing antigen specific tolerance in enzyme 
replacement therapies [122].  Weekly serum samples were obtained from all study 
animals via tail vein for ADA and PK analyses.  In addition, PK samples were taken pre-
dose in addition to 0.5, 2, 8, 24, 72, 120, and 168 hours post-dose in the first and fourth 
weeks.  All serum samples were stored at -60 °C to -80 °C until analysis.?
???????????????????????????????????
?
 The ADA assessments were performed using the universal indirect species-
specific assay (UNISA) as described previously [104, 115, 127].  Briefly, a bare 
standard-bind MSD 6000 plate was coated overnight with mAb1 for sample ADA 
capture, then blocked, and washed.  Serum samples were diluted 1:200 in 5 × KPL buffer
that was untreated (screening test) or contained excess antibodies (confirmatory test).  
The diluted serum samples were then added to the MSD plate for an extended incubation. 
Following that incubation, a ruthenylated rabbit anti-rat IgG (whole molecule) (Sigma-
Aldrich, St Louis, MO) was added.  The plates were read using the SECTOR® Imager 
6000 plate reader (Meso Scale Discovery® (MSD), Gaithersburg, MD), and the response 
measured as electrochemiluminescence (ECL) units.  Pooled normal rat serum (PNRS) at 
0, 100, or 500 ng/mL of anti-human IgG chimeric antibody were analyzed on every plate 
as quality controls.  For the screening assay, sample results were expressed as a ratio of 
the sample ECL to the negative control ECL (PNCS) as a signal to noise ratio (S/N).  
Analysis of specificity to variable and framework regions of mAb1 was performed by 
competitive inhibition of the screening assay signal with excess mAb1 or an irrelevant 
antibody with the same framework but different CDR as mAb1.  For the specificity and 
competitive binding analysis, the ratio of the treated S/N compared to the untreated S/N 
was expressed as a percent depletion.  No acid dissociation was performed for this assay 
format.  Samples were considered ADA-positive in screening if S/N>1.5 and signal 
depleted more than 20% in either confirmatory test. The sensitivity of the assay is 64 
ng/mL of anti-human IgG chimeric antibody. The assay is able to tolerate 20 μg/mL of
excess therapeutic in the presence of 500 ng/mL of antihuman IgG chimeric antibody. 
?????????????????????????? ????????? ??????????????????
?
An ECL based method to detect unbound mAb1 (not complexed with ADA) was 
used as described previously [104].  Briefly, standard streptavidin-coated plates (Meso 
Scale Discovery® “MSD”; Gaithersburg, MD) were passively coated with the biotin-
labeled murine idiotypic monoclonal antibody against the CDR region of mAb1 (clone 1, 
31
Lot 2579060 # 2, Amgen Inc., Thousand Oaks, CA).  The standard and quality controls 
were made by spiking the mAb1 into 100% SD rat serum and diluted 1:30 in an assay 
buffer (1× PBS with 0.5 M NaCl and 0.5% Tween 20) prior to loading into the wells.  A 
ruthenium-labeled murine monoclonal antibody against the CDR region of mAb1 
antibody (clone 2, Lot 2566770 # 3, Amgen, Inc.CA) was used to detect the captured 
mAb1. Both capture and detection antibodies were characterized as anti-idiotype specific 
with ability to neutralize mAb1. Following another wash step, a tripropylamine read 
buffer (MSD®, Gaithersburg, MD) was added to the plate. The plate was then read using 
the SECTOR® Imager 6000 Instrument (MSD, Gaithersburg, MD) equipped with 
Discovery Workbench software (v3.0.18). The final readout was measured and reported 
in ECL units. The range of this analytical method was 0.03–10 μg/mL. 
???????????? ???????
?
ADA responses to the variable (CDR), framework (Fc), or variable + framework 
portions of the TP, as well as pharmacokinetics were evaluated in the following analyses:   
? Fisher’s exact test was implemented at each dose to evaluate if the treatment 
of animals with immune suppression regimens significantly reduces the 
incidence of ADA when compared to mAb1 alone treated animals.  
? To assess the dose dependency of the time profile of ADA response S/N 
ratios, a Repeated Measure Analysis of Variance (RMANOVA) model was 
implemented on natural log transformed S/N ratios for each suppression 
regimen with dose group, week and interaction between dose group and week 
as fixed effects, and subject as random effect.  
? To assess if immunosuppression can significantly reduce the magnitude and 
onset of ADA a mixed effect model with compound (mAb1, mAb1+Tac/Sir, 
or mAb1+Mtx), dose, and interaction between compound and dose as fixed 
effects was implemented on natural log transformed ADA parameters (S/N at 
each time point, maximum S/N, and time of first ADA).  A final model 
assuming variance heterogeneity and with the smallest corrected Akaike 
information criterion (AICC) was selected for statistical analysis. 
? To assess if the immunosuppression can significantly increase mAb1 
exposure, a mixed effect model with suppression regimen, dose, and 
interaction between suppression regimen and dose as fixed effects was 
implemented on natural log transformed PK parameters (AUC (mg/mL*hrs), 
AUC Week 1, AUC Week 4, and Cmax). 
?
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?
?
?????????????????????????????????????????????????? ?????
?
 The following sections cover the impact of immune suppression on 
immunogenicity of mAb1 dosed in a rat model.  
Incidence of Anti-mAb1 Immune Response 
ADA incidence increased stepwise with mAb1 dosage, while immune suppression 
curtailed this effect (??????????).  UNISA, a modified ELISA method (described above), 
was utilized to compare serum levels of ADA.  Treatment with mAb1 alone resulted in  
50%, 83%, and 100% incidence in low, moderate, and high dosages, respectively.  At 
least half of these anti-drug antibodies were specific to the variable, complimentarity 
determining region (CDR), of mAb1.  Tacrolimus/sirolimus eliminated all ADA at 
moderate (50 mg/kg) mAb1 dose (P<0.01).  This treatment also reduced incidence by 
33% (not significant) and 66% (P<0.05) in low- and high doses of mAb1.  Methotrexate 
lowered ADA incidence less effectively than tacrolimus/sirolimus: 50% in moderate- and 
high dose groups.  Surprisingly, 17% more animals receiving methotrexate with 0.01 
mg/kg mAb1 developed anti-drug antibodies.  In the high dose cohorts, immune 
suppression also caused a shift in ADA epitope from CDR to framework, fragment 
crystallizable (Fc), portions of mAb1. 
Magnitude and Onset of Anti-mAb1 Immune Response 
Both modes of immune suppression, tacrolimus/sirolimus and methotrexate, 
lowered the magnitude as well as delayed the onset of anti-mAb1 antibodies     (???????
???).  The magnitude of immune response was measured in serum as a signal:noise (S/N 
= ratio of post-dose:pre-dose ECL) utilizing UNISA.  Control animals that tested positive 
for ADA did so within one week (168 hours) of mAb1 treatment (???????????????????).
When averaged with ADA-negative rats in their groups, onsets were 336 hours for low- 
and moderate doses of mAb1 and 504 hours for high dose mAb1.  Tacrolimus/sirolimus 
significantly lowered ADA magnitude within all dosed groups by week 3 (504 hours) 
after commencing mAb1 treatment (P<0.05).  Furthermore, Tac/Sir groups showed more 
than 70-fold lower maximum S/N for low and high mAb1 doses (P<0.01) (?????????).
Methotrexate outperformed tacrolimus/sirolimus in mitigating magnitude and delaying 
ADA onset (P<0.01) when co-administered with 300 mg/kg mAb1 (???????????????????
???).
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?
???????????? ??????????????????????????????????????????????????????????
????????????
Serum from rats (n=6 per group) dosed with mAb1 alone, tacrolimus + sirolimus 
(Tac/Sir) co-treatment, or methotrexate (Mtx) co-treatment, was analyzed for ADA 
response via universal indirect species-specific assay (UNISA).  ADA were assessed for 
specificity against CDR (α-variable), Fc (α-framework), or CDR + Fc (α-both) epitopes 
of mAb1 and percent incidence shown.  Fisher’s exact test utilized to calculate 
significance of immune suppression vs. mAb1 alone (shown in parentheses where 
applicable).  *p<0.05, **p<0.01?
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?
???????????? ??????????????????????????????????? ??????????????????? ?????
????????????????
Universal indirect species-specific assay (UNISA) was utilized to detect ADA. Signal to 
noise (S/N) was calculated as the ratio of post-dose:pre-dose 
electrochemiluminescence. Positive ADA threshold was set to S/N>1.5 (red dashed 
line). Average ADA magnitudes among ADA-positive animals in each group is plotted 
against time (A-C). Maximum ADA S/N (D-F, table) and time of ADA onset (table) 
from all rats in each group were averaged. Repeated measure ANOVA (RMANOVA) as 
mixed model implemented on natural log transformed S/N was used to determine 
statistical significance (shown in parentheses where applicable). *P<0.05, **P<0.01, *** 
P<0.0001?
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??????????? ?????????????????????? ????????? ???????????????????????????
?????? ?????????????
?
? ???? ??? ? ???? ?????
?????
?????
????????
?????????? ?????????????????
???
? ?? ?
????? ????
????????
???
? ??
0.01 mAb1 510.6 129 504 37
mAb1 + 
Tac/Sir
3.2 (0.0171) 121 672 0
mAb1 + 
Mtx
253.3 94 476 35
50 mAb1 298.6 134 392 52
mAb1 + 
Tac/Sir
1.7 (0.0048) 22 N/Aa N/Ab
mAb1 + 
Mtx
3.0 (0.0121) 100 588 (0.0054) 24
300 mAb1 323.9 97 504 21
mAb1 + 
Tac/Sir
2.6 (0.0019) 49 1568c (<0.0001) 31
mAb1 + 
Mtx
2.9 (0.0037) 77 1400c (<0.0001) 33
Repeated measure ANOVA (RMANOVA) as mixed model implemented on natural log-
transformed S/N was used to determine statistical significance (shown in parentheses 
where applicable). 
a No sample positive for DNA 
b ≤1 sample positive for ADA 
c Time points not depicted on graph 
?
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???????????????????????????????????????????? ????
?
The following sections cover the impact of immune suppression on the exposure 
of mAb1 dosed in a rat model. 
Immune Suppression on Free Drug Levels 
Although both forms of immune suppression initially depressed the quantity of 
free mAb1 in circulation, they boosted drug levels by week 4 (?????????????).  The 
concentration of mAb1 was plotted against time and the mean area under the 
concentration curve (AUC) determined for each group.  By the end of week 1, 
tacrolimus/sirolimus significantly lowered AUC by 67% (P<0.001) and 40% (P<0.05) in 
low- and moderate dose groups.  Methotrexate likewise reduced week 1 AUC by 49% 
and 52% at low- and high mAb1 dosages, respectively (P<0.01).  Tacrolimus/sirolimus 
immune suppression boosted free drug above mAb1 controls by 3- and 10-fold at the two 
highest treatments at week 4 (P<0.01).  Methotrexate also increased mAb1 exposure by 
3- and 6-fold at moderate- and high dosages at the latter time point (P<0.05). 
?
Anti-mAb1 Antibodies on Free Drug Levels 
Control groups exhibited a drastic decrease in circulating drug when test subjects 
developed ADA to mAb1, whereas this effect was tempered with immune suppression 
regimens.  By week 4, ADA-positive rats showed 5-fold and 7-fold lower AUC in low- 
and moderate-dose control groups (??????????????????).  In contrast, the highest 
discrepancy based on ADA status in experimental subgroups at 4 weeks was 22% with 
low dose mAb1+tacrolimus/sirolimus (???????????) and 43% with moderate dose 
mAb1+methotrexate (???????????).  Though statistical analyses did not show significant 
differences based on the development of ADA (?????????), general trends suggest that 
immune suppression could allow for better approximation of free drug levels if 
therapeutics are prone to immunogenicity. 
???????????
?
Preclinical studies of human therapeutic proteins in rodents and nonhuman 
primates are often associated with high immunogenicity.  We evaluated two regimens of 
immune suppression, methotrexate and tacrolimus plus sirolimus induction, with the goal 
of identifying a means to study drug pharmacokinetics without anti-drug antibody 
interference.  These treatments were selected because of their clinical pervasiveness in 
enzyme replacement therapies, graft-versus-host prophylaxis, and autoimmune disease 
management to mitigate ADA responses.  Inducing immunological tolerance can aid in 
pharmaceutical development of biologics and viral vectors, further improving patient  
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???????????? ????????????????????????????????????????????????
Area under the concentration curve (AUC) was calculated as free mAb1 concentration 
determined from ELISA plotted against time (mg/mL*hrs) for each treatment.  The 
mAb1 exposures were compared between anti-drug antibody (ADA) negative and 
positive animals (a) as well as in the presence or absence of immune suppression (b). 
Statistical significance was determined by one way ANOVA of natural log transformed 
PK parameters.  *P<0.05; **P<0.01, ***P<0.001 
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??????????? ???? ?????????????? ????????????????????????????????????????
??????????????????????????????? ?????????????????????????????????????????????
???????????????????
? ??????? ? ???????
?????
?????
????????
??????????
?????????
????????
????????
????????? ????
???????? ?
?????????
????????
????????
?????????
?????
????????
0.01 mAb1 0.4301 0.3370
mAb1 + 
Tac/Sir
0.8715 <0.0001 0.3487 0.6274
mAb1 + 
Mtx
0.0699 0.0021 0.9299 0.6529
50 mAb1 0.5580 0.3419
mAb1 + 
Tac/Sir
N/A 0.0159 N/A 0.0011
mAb1 + 
Mtx
0.5236 0.1918 0.1107 0.0013
300 mAb1 N/A N/A
mAb1 + 
Tac/Sir
0.0972 0.4335 0.3929 0.0092
mAb1 + 
Mtx
0.1015 0.0009 0.5760 0.0178
Statistical significance was determined by one way ANOVA of natural log transformed 
PK parameters 
N/A not applicable 
? Anti-drug antibody (ADA) negative and positive animals 
? Presence or absence of immune suppression 
?
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outcomes.  Our data demonstrate that these treatments can successfully lower antibody 
responses in animals to humanized therapeutics and boost amounts of drug in circulation. 
Combination tacrolimus/sirolimus better reduced ADA incidence and magnitude 
although methotrexate proved more efficacious with the highest dosage of mAb1.  
Tacrolimus/sirolimus treatment more than halved ADA incidence across dosages and 
consistently outperformed methotrexate in this regard (??????????). Maximum ADA 
signal:noise also fell with tacrolimus/sirolimus to less than 1% that of control (??????????
???).  Methotrexate similarly elicited at least a 50% drop in ADA incidence in the higher 
dosed groups.  Despite higher incidence with 300 mg/kg mAb1+methotrexate relative to 
combination immunosuppressant therapy (???????????), the ADA magnitudes were 
below those of the matched tacrolimus/sirolimus cohort (??????????).  In addition,  
methotrexate further delayed the average onset of antibody response by 112 hours 
relative to tacrolimus/sirolimus with high dose mAb1 (?????????).
  
Noteworthy, is that methotrexate treatment showed an enhanced incidence of 
ADA in the lowest dose group (67%) compared to control (50%).  This additional 
response was CDR specific (?????????) and had a similar magnitude to that observed in 
the mAb1 alone group (???????????).  One reason for a less effective immune 
suppression by methotrexate at this dosage could be the difference in frequency of 
immune suppressant administration.  While methotrexate was administered three times 
(0, 24, and 48 hours) after the first mAb1 dose, tacrolimus was administered weekly 
(with sirolimus only on day 1).  A methotrexate regimen identical to that used in this  
study was found to sustain ADA responses up to 4 months post ERT infusion of 
recombinant human acid α-glucosidase (rhGAA) of mice with Pompe disease [128].  
Tolerance was extended to 8 months with a 3 week, low dose methotrexate regimen 
[129].   Both studies dosed rhGAA at 20 mg/kg and described expansion of regulatory B 
cells that proved crucial in suppressing anti-rhGAA antibodies.  It is therefore possible 
that insufficient mAb1 was present in circulation in the 0.01 mg/kg dosed group to induce 
methotrexate-mediated tolerance.  When higher doses of mAb1+methotrexate were used, 
ADA magnitudes fell throughout the time course extending up to 8 weeks after initial 
drug treatment (??????????????????).  To this end, utilizing additional cycles of 
methotrexate along with higher doses of TP may further mitigate anti-drug immune 
responses. 
  
Additionally, the different mechanisms of action employed by the immune 
suppressants used in this study could also have contributed to their varying efficacies.  
Tacrolimus is a macrolide lactone that exerts its immunosuppressive properties by 
reducing interleukin-2 (IL-2) production by T-cells.  Similarly, sirolimus (rapamycin) is a 
bacteria-derived macrolide that prevents activation of T cells and B cells by inhibiting 
their response to IL-2.  In contrast, methotrexate suppresses the clonal expansion of T 
effector cells that eventually drive antigen specific memory [130].  Thus, repeated 
tacrolimus/sirolimus administration may have prevented primary immune responses to 
mAb1 with each weekly dose.  The sole methotrexate regimen, however, could have only 
temporarily enabled mAb1 tolerance and delayed the onset of secondary antibody 
responses with even greater magnitudes (??????????????????).
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??????????? ???????????????????????????????????????????????????????????????????
????????????????????????????????????????????????
?????
???????? ??????????
??
?????????
??
??????????
??
????? ?????? ????????
0.01 mAb1 17% 0% 33% 50%
mAb1 + 
Tac/Sir
0% 0% 17% 17% 0.27273
mAb1 + Mtx 33% 0% 33% 67% 0.87879
50 mAb1 83% 0% 0% 83%
mAb1 + 
Tac/Sir
**0% 
(0.00758)
0% 0% **0% 0.00758
mAb1 + Mtx
*17% 
(0.04004)
0% 17% 33% 0.12121
300 mAb1 83% 0% 17% 100%
mAb1 + 
Tac/Sir
**0% 
(0.00758)
17% 17% *33% 0.0303
mAb1 + Mtx 33% 17% 0% 50% 0.09091
Fishers exact test utilized to calculate significance of immune suppression vs. mAb1 
alone (shown in parentheses where applicable) 
*p<0.05;  **p<0.01 
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Immune modulation was found to alter the level of free drug circulating in 
animals.  Drug concentrations declined in ADA-positive control animals relative to their 
ADA-negative counterparts by week 4 (??????????????????). These differences 
disappeared in the groups treated with immunosuppressant regimens, which also 
displayed significantly lower ADA magnitudes. Animals in the higher dosed groups 
treated with immune-altering effects exhibited elevated levels of free drug at week 4 as 
well. Taken together, these observations suggest that lower ADA magnitudes correlate 
with improved retention of an otherwise immunogenic monoclonal antibody therapeutic.  
Ongoing animal and clinical studies continue to optimize drug-immunosuppressant 
combinations for specific medical indications.  Cyclosporin A with 
azathioprine has been utilized to reduce humoral immunity against recombinant 
iduronidase for Mucopolysaccharidosis I [131].  Methotrexate, both alone [121, 128] and 
when combined with rituximab ± gammaglobulins [122] can boost the effectiveness of 
rhGAA enzyme replacement therapy for Pompe disease.  Similarly, methotrexate-
thymoglobulin [129] and mycophenolate mofetil (MMF) [132] therapies prolonged 
allograft survival in transplant mice and patients, respectively.  Lysostaphin, a powerful 
antibiotic against Staphlylococcus aureus that also promotes ADA responses, can be 
made more effective at clearing infection with deletion of T cells specific to the drug in 
murine models [133, 134].  Finally, immune suppression continues to play an essential 
role in cancer.  Patients with mesothelioma who received the active drug, SS1P, together 
with pentostatin/cyclophosphamide immunosuppression tolerated more treatment [135]. 
Given the expansion of immune suppression applications, additional studies will 
be essential to streamlining its use in preclinical drug development.   A broader selection 
of immunosuppressant techniques, such as those noted above, could further aid in 
selection of an optimal regimen.  Beyond examining ADA, it will also be important to 
examine the transition of B cell, T cell, and antigen-presenting-cell phenotypes following 
co-dosing with immune modulators.   Transcriptomic, cell marker, and cytokine analyses 
will contribute valuable data to our understanding how immune processes are subverted 
in animals when challenged with humanized therapeutics.  Preliminary ELISpot 
experiments in which rat splenocytes were incubated with mAb1 along with methotrexate 
or tacrolimus/sirolimus showed no mAb1-specific T cell activation in both immune 
suppressed groups (unpublished observation).  Instead, it is anticipated that regulatory 
markers IL-10, TGF-b, and Foxp3 will be most upregulated.  
Concerns regarding preconditioning with immune suppressants include the fact 
that co-therapy can change the overall toxicology profile and alter drug efficacy.  For the 
current study, animals displayed only minor symptoms of immunosuppressant toxicity in 
that some seemed transiently lethargic, dehydrated, and lost weight immediately after the 
3 methotrexate administrations.  This frailty seemed to resolve within one week after 
methotrexate administration ceased.  To address this issue, one solution is to retain an 
immunosuppressive regimen alone arm in the study that will help understand any 
organ/tissue toxicities caused by such agents.  However, the combined effect and 
interaction of the co-therapy agents with the therapeutic protein will be a challenge to 
tease out.  As the regimens used in this study were short lived, the boost in circulating 
drug evidences a greater benefit than risk in mitigating immunogenicity.  The authors 
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recommend that such immunosuppressive regimens be tailored to minimize side effects 
in test subjects and maximize parallel conditions anticipated in human trials.   
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????????????? ?????????????????????????????????????? ????
?????? ???????????????????
?????????????
?
The number of therapeutic proteins approved or under development for human 
use has markedly increased this decade.[1] Many of the approved products are IgG1 or 
IgG2 recombinant monoclonal antibody based biotherapeutics that have been engineered 
to be close to endogenous human mAbs. Fully human biotherapeutics such as 
monoclonal antibodies are designed to be less immunogenic in humans, but are often 
immunogenic when administered to preclinical animal models during drug development, 
and are associated with the formation of anti-drug antibodies (ADA) in those species. 
ADA formation may not only neutralize the pharmacologic activity of the therapeutic 
protein, and hence impact its efficacy, but may also modulate its pharmacokinetics and 
thus systemic exposure by forming immune complexes and modulating its clearance.[92] 
Clearance of a protein therapeutic through an immune response has been well 
documented, with the primary result being enhanced clearance of the immune 
complex.[92, 104, 136] The mechanism of clearance by ADA is either through 
phagocytosis of the immune complex by the reticuloendothelial system or through the 
complement system, which will opsonize the immune complex and deposit it on an 
erythrocyte which will carry it to the liver or spleen to be phagocytosed by 
macrophages.[137, 138] If the immune complex is cleared via the reticuloendothelial 
system, the Fcƴ receptors on the Kupffer cells and sinusoidal endothelial cells in the liver, 
monocytes and macrophages in the spleen and platelets will recognize the constant 
domain on the monoclonal antibody and clear the immune complex.[139-142] The 
clearance of the ADA therapeutic protein complex can be highly variable though. 
Variability in clearance of an immune complex is mainly due to the polyclonal nature of 
an immune response. Each ADA has a different affinity to the biotherapeutic’s antigenic 
site, which leads to variable rates of binding to the biotherapeutic, with a higher affinity 
ADA reaction leading to larger immune complexes and a faster clearance once an 
immune reaction occurs against the therapeutic protein.  An example of the clearance 
variability caused by variable interaction of ADA with the therapeutic protein has been 
exemplified for interleukin-6, where small immune complexes with only one of two 
ADAs had a sustaining effect in the systemic circulation, while interaction with three or 
more ADA resulted in larger immune complexes with increased clearance of the drug-
ADA complex.[105, 143] 
The highly variable effect of ADA formation on the exposure to a therapeutic 
protein may cause problems in toxicity studies in preclinical species, as well as the 
preclinical pharmacokinetic assessment of the protein therapeutic. Toxicity studies 
require that a certain systemic exposure is met in animals over time, in order to observe 
any toxic effects. If formation of ADA occurs and leads to an increase in clearance of the 
therapeutic protein, the targeted systemic concentrations will likely not be achieved in 
many of the studied animals. Without meeting the target concentration in many of the 
animals, the toxicity study will not be powered appropriately to detect the presence or 
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absence of any relevant toxicity with adequate statistical significance.  The variable 
increase in clearance of the therapeutic protein secondary to ADA formation and the 
resulting variability in concentration-time profiles will also complicate a reliable 
pharmacokinetic assessment of the therapeutic protein. Model-based analyses provide a 
potential pathway to overcome these limitations by simultaneously analyzing ADA 
positive and ADA negative animals and thereby adequately characterizing the impact of 
ADA on the pharmacokinetic profile of a therapeutic protein in a preclinical animal 
model.[92] 
Therefore, the objective of this study was to characterize the impact of ADA 
formation on the pharmacokinetic profile of a fully human mAb in rodents using a 
model-based analysis approach. The analysis was based on data from a previous study 
performed by our group.[89] In this study, the pharmacokinetics and immunogenicity of a 
fully human monoclonal antibody were investigated in the presence or absence of two 
immunomodulation strategies at different mAb dose levels, within a naïve rat model. 
Data from each of the studied nine groups was used to inform our PK/ADA model 
allowing it to estimate the fully human mAb’s PK parameters, and to characterize and 
quantify the effect immunogenicity has on the mAb’s pharmacokinetics. The results of 
this analysis are reported in this manuscript.  
????????
?
?
??????????????????
?
The preclinical study used as basis for the model-based analysis approach has 
previously been reported elsewhere in detail.[89] In brief, the following are the key 
features of the study: 
?
????????????
?
Male Sprague Dawley rats (Strain: Crl: CD) were sourced from Harlan 
(Indianapolis, IN) at 6 weeks of age, weighing 250–300 g. Three animals were housed in 
each cage during the study with free access to standard food and water and were 
maintained on a 12/12-hour light/dark cycle. Animals were allowed to acclimate for 1 
week before study initiation. This study was conducted in accordance with an approved 
protocol by the Institutional Animal Use and Care Committee at the University of 
Tennessee Health Science Center (Memphis, TN). 
?????????????
?
The therapeutic protein used in this study as a model drug was a fully human 
IgG2 monoclonal antibody (mAb1), supplied by Amgen Inc. (Thousand Oaks, CA). The 
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concentration of the original solution was 71.8 mg/mL, which was diluted to the desired 
concentration for dosing, if necessary prepared just prior to dosing in a sterile container. 
If dilution was necessary, which was the case for the groups administered 0.01 mg/kg of 
mAb1, the original solution was diluted with 0.9% saline solution to the desired 
concentration of 0.01 mg/mL in order to allow for more accurate dosing. MAb1 does not 
have an endogenous target in rodents. 
?????????????
?
Animals were divided into nine groups (n =3-6 each) according to the dose of 
therapeutic protein and immunosuppressive regimen (?????????). The therapeutic protein 
was dosed to all rats subcutaneously at the back of the neck, rotating between 3 injection 
sites: left, center and right. Animals were given four weekly subcutaneous 
administrations of either 0.01 mg/kg, 50 mg/kg or 300 mg/kg of mAb1. At each dose 
level, two groups received immunosuppression with either tacrolimus (2mg/kg) (Astellas, 
Deerfield, IL) and sirolimus (6 mg/kg) (Wyeth Pharmaceuticals Inc., Philadelphia, PA), 
or methotrexate (5 mg/kg) (APP Pharmaceuticals, LLC, Schaumburg, IL). Tacrolimus 
was given subcutaneously at the lower back, by the hind leg, with each dose of the 
therapeutic protein. Sirolimus was given through oral gavage with only the first dose of 
mAb1. Methotrexate was given through intraperitoneal injection in a three dose cycle, 
shown to be efficacious in another study, [129] starting with the first dose of mAb1, then 
on the second day of the study and third day of the study. 
?????????????????????? ????????
?
Serial blood samples (0.3 mL) were obtained from the tail vein under isoflurane 
anesthesia and placed into nonheparinized microhematocrit tubes (Thermo Fisher 
Scientific, Pittsburgh, PA). Samples were obtained weekly for ADA and pharmacokinetic 
analysis, as well as pre-dose and 0.5, 2, 8, 24, 72, 120, and 168 h post-dose in the first 
and fourth week for pharmacokinetic analysis. Blood was allowed to clot at room 
temperature for 30–45 minutes, and serum was separated by centrifugation at 2000 g for 
20 minutes at 4°C. Serum was divided into aliquots and stored at -60 - −80°C until 
analysis. 
??????????????????????? ??????????????????
?
A sandwich enzyme-linked immunosorbent assay was used to quantify mAb1 
concentrations in rat serum samples. Standard streptavidin-coated 96-well microplates 
(Meso Scale Discovery® “MSD”, Gaithersburg, MD) were passively coated with the 
biotin-labeled murine idiotypic monoclonal antibody against the CDR region of mAb1 
(Clone 1, lot 2579060 # 2, Amgen Inc., Thousand Oaks, CA). Standards and quality 
controls were made by spiking mAb1 into Sprague Dawley rat serum and dilution 1:30 in  
?
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??????????? ?????????? ??????
?????????? ????????????????????????????
??????
????
Low Dose None 1  (3)
(0.01 mg/kg) Tacrolimus & Sirolimus 2  (6)
Methotrexate 3  (3)
Moderate Dose None 4  (4)
(50 mg/kg) Tacrolimus & Sirolimus 5  (5)
Methotrexate 6  (6)
High Dose None 7  (4)
(300 mg/kg) Tacrolimus & Sirolimus 8  (6)
Methotrexate 9  (4)
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an assay buffer (1X PBS with 0.5M NaCl and 0.5% Tween 20) prior to loading into the 
wells. A ruthenium-labeled murine monoclonal antibody against the CDR region of 
mAb1 (Clone 2, lot 2566770 # 3, Amgen Inc., Thousand Oaks, CA) was added for 
detection of captured mAb1. Following another wash step, a tripropylamine read buffer 
(MSD®, Gaithersburg, MD) was added to the plate.  The plate was then read using a 
SECTOR Imager 6000 instrument (MSD®, Gaithersburg, MD) equipped with Discovery 
Workbench software (v3.0.18). The resulting electrochemiluminescence (ECL) was 
measured and reported in ECL units. The range of this analytical method was 0.03–10
μg/mL.
???????????????????????? ????
?
A Universal Indirect Species-specific Assay (UNISA) was used to measure the 
relative amount of ADA in the rat serum samples, as described previously.[104, 127, 
144] A bare standard-bind MSD 6000 plate was coated overnight with mAb1 for sample 
ADA capture, then blocked, and washed. Serum samples were diluted 1:200 in 5× KPL 
buffer that was untreated (screening test) or contained excess antibodies (confirmatory 
test). The diluted serum samples were then added to the MSD plate for an extended 
incubation. Following that incubation, a ruthenylated rabbit anti-rat IgG (whole 
molecule) (Sigma-Aldrich, St Louis, MO) was added. The plates were read using the 
SECTOR® Imager 6000 plate reader (Meso Scale Discovery® (MSD), Gaithersburg, 
MD), and the response measured as electrochemiluminescence (ECL) units. Pooled 
normal rat serum at 0, 100, or 500 ng/mL of antihuman IgG chimeric antibody were 
analyzed on every plate as quality controls. For the screening assay, ECL signal of the rat 
serum prior to therapeutic protein dosing was compared to ECL signal after the 
therapeutic protein’s dosing using ???????????? forming a signal-to-noise ratio (S/N), 
used as the measurement for ADA in each sample. A signal-to-noise ratio of greater than 
1.5 was set as a positive ADA measurement. 
?
?
? ??????????????????
???????????????????
?      ???????
No acid dissociation was performed for this assay format. The sensitivity of the 
assay is 64 ng/mL of anti-human IgG chimeric antibody. The assay is able to tolerate 20 
μg/mL of excess therapeutic in the presence of 500 ng/mL of antihuman IgG chimeric 
antibody. 
?????????????????????????????????????
?
?
???????????????????????????????
?
The serum concentration–time profile of mAb1 for the study population was 
evaluated by nonlinear mixed effects modeling (NONMEM, version VII, ICON plc, 
Dublin). The first-order conditional estimation (FOCE) method was used for all 
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parameter estimations. During model evaluation Pirana (Pirana, version 2.9.2, Pirana 
Software & Consulting BV, http://www.pirana-software.com), Perl speaks NONMEM 
(PSN, version 4.2.0, http://psn.sourceforge.net) and R (R, version 3.0.1, The R 
Foundation for Statistical Computing) were used. 
??????????????????????????? ??????
?
The pharmacokinetic of mAb1 concentrations were described using 
compartmental pharmacokinetic modelling. One- and two-compartment models with 
first-order absorption, distribution and elimination constants were tested. Estimated 
pharmacokinetic parameters were absorption rate constant, apparent volumes of 
distribution and clearances. These values were apparent because mAb1 was administered 
extravascularly by subcutaneous injection. Competing structural models were compared 
using Akaike’s information criterion (AIC), defined as follows: AIC = −2LL + 2p, where 
−2LL is the twice the negative log-likelihood and p is the number of model parameters to 
estimate.  
???????????????????? ??????
?
ADA was incorporated into the pharmacokinetic structural model similar to a 
pharmacodynamics effect being incorporated into a classic PK/PD model.[145]  Different 
alternative approaches were explored to integrate ADA formation into the 
pharmacokinetic model, but several general assumptions were followed during model 
development process, similar to what has been suggested by others.[146] 
1. No ADA is formed during the first dosing interval (7 days). This assumption 
is made because it has been reported that the lag period for ADA to rise 
during the primary immune response varies anywhere from 7 days to several 
weeks.[147] 
2. After the first dose, ADA has the potential to be produced at any time with an 
estimated rate constant of Kada, and once produced its appearance in the 
systemic circulation is delayed through a set of lag compartments. 
3. From the lag compartments, ADA enters the central compartment with an 
overall time delay of Tlag. This time delay is represented by the parameter kt.
kt is the transfer rate constant of ADA between delay compartments and can 
be transformed into Tlag through ????????????.
4. PK parameters of free mAb1 are estimated from the animals that do not have 
an immune reaction, and thus are independent of ADA production. 
5. mAb1 will be bound by ADA with a molar rate of Kcomplex and will be 
irreversibly eliminated from the central compartment. 
?? ? ???????                      ???????
49
?????????????????????? ??????
?
The interindividual variability in pharmacokinetic parameters was described using 
an exponential model in ????????????, as follows:  
?? ? ??? ? ????       ???????
where θi is the estimated individual parameter, θTV is the typical value of the parameter 
and ηi is the random effect for the ith patient. The values of ηi were assumed to be 
normally distributed, with a mean of zero and variance ω2. Correlations between random 
effects were tested. Additive, proportional and mixed additive–proportional residual error 
models were tested.  
???????????
?
Several covariates were tested in our model and two were found to be significant 
covariates, as indicated by a drop in objective function value (OFV) of 3.84 or greater 
and a drop in BSV of greater than 10%. The two covariates were weight and dose level. 
Weight was used as a continuous covariate centered on the mean weight of all the 
animals in the study. The structure of the covariate model is shown in ????????????: 
?? ? ??? ?
???
??????
??
?       ???????
where Wti is the weight of the individual animal, Wtmean is the mean weight of the 
animals in the study and θc is the allometric scaling exponent. Dose level was used as a 
binary covariate for relative bioavailability in the highest dose group (300 mg/kg). At the 
highest dose level, the relative bioavailability appeared to decrease compared to both the 
0.01 mg/kg dose group and 50 mg/kg dose group. A potential explanation for this 
observation is a potential saturation of the neonatal Fc receptor (FcRn). FcRn typically is 
not saturated at doses given to human patients, but at extremely high doses such as the 
300 mg/kg given to study animals, the total (endogenous and exogenous) IgG 
concentration in serum was approximately doubled in this group, which may lead to an 
increase in the elimination of the mAb1 due to partial saturation of the FcRn salvage 
pathway. This same effect is also seen in patients with multiple myeloma who have 
highly elevated IgG levels.[43] Therefore, dose was used as a categorical covariate for 
bioavailability, and implemented as follows in ????????????: 
? ? ?? ? ?????
????        ???????
where the parameter estimate for the dose effect (θDose) was raised to the high dose effect 
(FcRn) which was either 0 or 1 depending on if the dosing group was 0.01 and 50 mg/kg 
or 300 mg/kg respectively.
50
?????????????????????????????????????????? ???????????????
?
Model development was guided by the standard diagnostic plots and plausibility 
of the parameter estimates. Interindividual, residual and covariate models were compared 
using −2LL and AIC. The model with the lowest significant −2LL value, assessed by a 
likelihood ratio χ2 test, and the lowest AIC, was selected. The individual influence of 
each covariate on each pharmacokinetic parameter, if biologically plausible, was tested 
using the likelihood ratio test with α = 0.05 (change in OFV≥3.84). The number of 
selected covariates was low, so no stepwise forward/backward covariate selection was 
needed. The covariates were kept in the final model if their influence was significant for 
α = 0.01 (change in OFV≥10.83), and resulted in a reduction in between-subject 
variability of 10% or more.  
The precision and stability of the model parameters was investigated by a 
stratified bootstrap analysis and a visual predictive check (VPC). Specifically, 500 
replicate data sets were generated through random sampling with replacement using 
individuals as sampling units. Stratification during the random sampling process was 
implemented to ensure that the bootstrap datasets adequately represented the original data 
with respect to the different doses administered, as well as immunomodulation strategies. 
The 90% confidence interval was constructed by observing the 5th and 95th percentiles of 
the parameter distributions resulting from the bootstrap runs. To ensure that the model
accurately represents the observed data, a VPC was performed. The final model was used 
to simulate 2000 replicates, and a 95% prediction confidence interval was constructed 
from the simulated concentration time profiles and compared with the observed data. We 
stratified the VPC according to dose and whether the animal was ADA positive and ADA 
negative.  
????????????
?
To demonstrate the influence of ADA formation on the pharmacokinetic profile in 
a study population, studies with different percentages of animals with ADA formation 
were simulated 2000 times. The simulated study populations represented a percentage of 
ADA formation between 0% and 100%. By simulating the effect ADA formation can 
have on the concentration-time profiles of a biotherapeutic in a study population, the 
model facilitates to visualize and quantify the effect ADA will have on the therapeutic 
protein’s overall exposure in the animals and predict the range of concentration-time 
profiles in a study population treated with a therapeutic protein in the presence and 
absence of an immune reaction. This will allow for a power analysis to be performed that 
will provide information for determining the minimum number of animals required to 
meet an average exposure over time as prerequisite for a successful toxicology study. 
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????????
?
The current study provides a model-based analysis on the time-dependent 
formation of ADA and its impact on the systemic exposure of a biotherapeutic. The 
analysis was based on data from a previously performed study by our group,[89] in which 
different immunosuppressive regimens were explored with regard to their effect to 
modulate ADA formation after administration of a human monoclonal antibody, mAb1, 
to rats. Overall, 41 animals were used to inform the PK/ADA model, some of which were 
ADA positive and some ADA negative. The observed mAb1 average concentration-time 
profiles from this study are shown for each mAb1 dosing group in ??????????. The 
corresponding observed relative ADA measurements for each dose level and treatment 
group are shown along with the percentage of ADA formation in each group in ????????
???.
The PK/ADA model that best described the mAb1 concentrations over time is 
illustrated in ??????????. The pharmacokinetics were best described using a two-
compartment model with first-order absorption process, with an inter-compartmental 
clearance Q and clearance from the central compartment CL. The modeling of the ADA 
response was based on the observed relative ADA measurements, as well as the change 
in clearance not explained by the clearance CL predicted by the PK portion of the model. 
As defined in the modeling assumptions, the potential for ADA generation starts with the 
second dose. If ADA develops, the amount of ADA produced, represented by the ADA 
molar formation rate (Kada parameter estimate), is informed by the relative amount of 
ADA measured in the animals which were ADA positive. To account for the time delay 
to develop an immune response, the ADA molar formation rate is introduced into a series 
of delay compartments, and subsequently enters the central compartment, with a total 
time delay Tlag. The number of the delay compartments n can be flexible, but as n 
increases it will result in a better resolution and better approximation of a true (switch-
like) delay.[146] The value of n was chosen to be 5 in our model, which is supported by 
previous reports.[146, 148] The transfer rate constant kt between the ADA depot and all 
the delay compartments is derived from Tlag (????????????). Once the ADA reached the 
central compartment, the ADA-mediated drug elimination rate in the PK/ADA model 
was estimated through the kcomplex parameter. The kcomplex parameter represents the ADA 
binding to mAb1 and irreversible elimination of the formed immune complex from the 
circulation, and was dependent on the deviation in clearance not explained by the 
clearance parameter CL in the PK portion of the model.  
Consequently, the developed PK/ADA model is characterized by the following 
set of equations (???????????? through ?????????????): 
?????
??
? ? ???? ???? ? ??      ???????
?????
??
? ? ?? ? ????? ? ?????? ? ?? ?? ???????    ???????
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?
???????????? ????? ???????????????????????? ???????????????????? ???????????
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?
???????????? ????? ???????????? ?????????????????????????????????????????
???????????????????? ?????
A. Observed relative ADA magnitudes for 0.01 mg/kg mAb1 dose group. Bar graph 
represents the percent of animals in each group that tested positive for an immune 
reaction at any time during the study. 
B. Observed relative ADA magnitudes for 50 mg/kg mAb1 dose group. 
C. Observed relative ADA magnitudes for 300 mg/kg mAb1 dose group. **This group 
had a washout period where ADA sample measurements were drawn weekly, which 
stretched from 672 hrs to 1344 hrs. 
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?
???????????? ????????????????
Structural PK/ADA model for immunogenicity assessment. With repeated dosing of the 
therapeutic protein (TP) an immune reaction may form against the TP.  If ADA develops, 
ADA molar rate injections, represented by the Kada parameter estimate, are introduced 
into a series of delay compartments, and subsequently enter the central compartment, 
with a total time delay Tlag. Once the ADA reaches the central compartment, the ADA-
mediated drug clearance is estimated by kcomplex. Kcomplex represents the ADA binding to 
and irreversibly clearing the mAb1 from the circulation. 
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? ??? ? ?? ? ???????? ? ???? ?
??
??
?    ???????
???
??
? ???? ? ???? ? ?? with Ad at time 0 = Dose  ???????
???
??
? ?? ? ???? ? ?? ? ? ?
??
??
? ? ? ??
??
? ?? ?
??
??
? ???????? ? ???? ?
??
??
?
          ????????
???
??
? ? ?
??
??
? ? ? ??
??
?      ????????
KADA is the molar rate of ADA moving into the ADA delay compartments. A1, A2
… Ai are the amounts of ADA in the delay compartments, and ADAp is the amount of 
free ADA in the serum. Ad is the amount of mAb at the subcutaneous absorption site, 
Ap is the amount of free mAb1 in the central compartment, and AT is the amount of free 
mAb1 in the tissue. Dose is the input dose for mAb1. The parameter kt is the transfer rate 
constant of ADA between delay compartments. Kcomplex is the second order association 
rate constant for the mAb1-ADA immune complex formation, representative of the ADA 
binding to mAb1 and elimination the ADA–drug complex. The parameter Q is the 
intercompartmental clearance of drug between serum and tissue. Vp and Vt are the 
volume of the central compartment and peripheral compartment, respectively. Ka is the 
first-order rate constant at which mAb1 is absorbed from the subcutaneous injection site 
into the central compartment. CL is the parameter that is representative of the clearance 
of the mAb1 in animals which do not form ADA. Frel represents the relative 
bioavailability between each of the dose levels. All the amounts used in these equations 
are in molar units. The parameter estimates of the PK/ADA model, their precision and 
their between-animal variability are summarized in ?????????.
The diagnostic goodness-of-fit plots of predicted vs. observed measurements as 
presented in ?????????? for the final model suggest that the PK/ADA model described the 
data adequately. All model based parameters were estimated with satisfactory accuracy 
(?????????). The visual predictive check plots in ?????????? indicate that there was no 
obvious model misspecification (??????????).  The precision of the model parameters 
were investigated by a stratified bootstrap analysis. 500 replicate data sets were generated 
through random sampling with replacement using individuals in the original data set as 
sampling units. Not surprisingly, a large interindividual variability in ADA parameters 
was observed. This was notably the case for Kcomplex and Kada, for which between subjects 
variability was 129% and 74%, respectively. This high variability can be rationalized by 
the fact that each individual’s immune system’s reaction to mAb1, or any antigen, will be 
different. This variability in each animal’s immune reaction is reflected in our model, as 
the mAb1-ADA complex elimination lead to an increase in clearance between 2 to 500 
fold compared to the clearance in individuals who did not form ADA. This increase in 
elimination was driven by the magnitude of ADA formation in a linear fashion, so with 
an increase in ADA (quantified as S/N) there was a constant increase in immune 
complex-mediated clearance. In summary, we could successfully develop a structural  
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??????????? ????????????????????
?
?????????? ????????? ??? ???????? ?????????????
Pharmacokinetic Parameters
CL (mL/day) 3.89 0.213 62.0 3.60-4.30
Vc (mL) 19.3 3.34 -- 9.76-20.7
Vp (mL) 43.7 8.89 -- 27.1-56.4
Dose Effect on F 0.801 0.0768 -- 0.738-0.863
Q (mL/day) 4.10 1.39 -- 2.98-7.54
Ka (day-1) 0.229 0.0276 65.0 0.208-0.298
ADA Parameters
Kada (nmol/day) 77.0 7.01 74.0 66.2-89.3
Tlag (day) 14.6 3.12 71.0 7.79-21.5
Kcomplex
(mL/(nmol*day))
0.530 0.00122 129.0 0.480-0.533
Allometric scaling coefficients  
??=0.75 (CL) 
??=1.00 (V1 and V2) 
57
???????????? ?????????????????????????? ???????????????????????? ????????
???????????????
58
?
???????????? ?????????????????????????
Visual predictive checks were stratified into 6 groups related to dosing group and ADA 
status. 
A. 0.01 mg/kg mAb1 dose group without immune reaction 
B. 0.01 mg/kg mAb1 dose group with 100% immune reaction 
C. 50 mg/kg mAb1 dose group without immune reaction 
D. 50 mg/kg mAb1 dose group with 100% immune reaction 
E. 300 mg/kg mAb1 dose group without immune reaction 
F. 300 mg/kg mAb1 dose group with 100% immune reaction 
?
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PK/ADA model that adequately described the concentration-time profiles of mAb1 
profiles in the presents and absence of ADA formation.  
?
???????????
?
We used pharmacokinetic modelling to investigate the effect ADA formation has 
on the concentration time profile and variability in systemic exposure for a human mAb 
in rodents. Similar models have been proposed by Chirmule et al., Perez Ruixo et al. and 
Chen et al. to evaluate the effect of immunogenicity on therapeutic protein 
pharmacokinetics.[92, 108, 146] Our PK/ADA model, as an extension to the above three 
models, is based on the assumption that the disposition of the therapeutic protein is 
affected by ADA-mediated clearance. It simultaneously captures the therapeutic protein’s 
pharmacokinetics as well as the ADA response, and permits the simulation of ADA 
production in preclinical species based on multiple dose studies.  
Serum concentration-time data for mAb1 and ADA responses were obtained from 
Sprague-Dawley rats given four consecutive doses of three different dose levels of 
mAb1, under three different immunomodulation strategies. The mAb1 pharmacokinetic 
parameters were estimated based on data obtained from the animals without an immune 
reaction to mAb1. The mAb1 profile was best described using a two-compartment model 
with first-order elimination rate, which is a common structural model used for many 
monoclonal antibodies.[4] We described mAb1 absorption kinetics using a first-order 
absorption rate (ka), with a mean estimate of 0.229 day−1. This value is close to what has 
been reported in other studies in humans, for example for omalizumab (?0.45 day−1) and 
efalizumab (?0.25 day−1).[149-151]  The mAb1 central volume of distribution (V1) in 
our study is 0.0544 L/kg (allometric scale comparison), a value which is typically seen 
for other monoclonal antibodies, as they are mostly confined to the vascular space and 
well perfused organs. The value of clearance (CL) estimated in the present study, is 3.89 
mL/day, a value similar the clearance of trastuzumab, another monoclonal antibody, in 
rats which was reported as 2.42 mL/day.[152] CL had a BSV of 62% which is high, but 
within what has been seen in other studies.[4] Intercompartmental clearance (Q) was 
estimated at 4.10 mL/day with a BSV that was not identifiable due to insufficient data. 
The magnitude and timing of the ADA responses can be directly visualized by the 
observed data and model-estimated ADA–time profiles of ADA (??????????).  The 
magnitudes of the ADA effect are described in the model by the parameters 
Kada and Kcomplex, while the timing of the ADA response is described by Tlag. Kada
represents the molar rate of ADA moving into the lag compartments, and eventually into 
the central compartment, for each individual. The parameter estimate for Kada was 
dependent on the measured ADA level (S/N) in ADA-positive animals. Kada continued to 
increase as the measured ADA S/N ratio increased over time. This parameter proved to 
be effective in estimating the amount of ADA moving into the central compartment, as 
seen in the individual animals that had an ADA formation reaction (??????????). Within 
these animals, the model adequately captured the overall level of ADA that increased 
over time, with the repeated drug dosing. This is consistent with the observed increase in  
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?
???????????? ???????? ????????????????????????????? ?????????
Average observed ADA magnitude over time vs. average model predicted ADA 
magnitude over time for each dose level, in the animals that tested positive for ADA 
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drug elimination throughout the study in ADA positive animals. The choice of using 
measured ADA S/N ratios rather than another method, like cumulative drug dose as used 
other modeling approaches [146, 153], is supported by the fact that across multiple doses 
(0.01, 50 and 300 mg/kg) the measured relative ADA in the animals which formed an 
immune reaction was not consistent within each dose level. Another reason we had to 
forgo using cumulative dose and inform our model with measured relative ADA is seen 
in ??????????, which shows the relative magnitudes of ADA formation across the three 
dose levels.  ?????????? shows an inverse relationship between dose and ADA 
magnitude, with the lowest dose of 0.01 mg/kg having the greatest magnitude of ADA 
response, followed by the 50 mg/kg dose and lastly the highest dose (300 mg/kg), a 
phenomenon that has also been reported in numerous other studies.[154, 155] In ???????
???, the magnitude of ADA formation can be seen, and though cumulative dose appears 
to be correlated with an increase in ADA S/N ratio within each individual mAb1 dose 
level, the fact that there is an inverse relationship between magnitude of ADA formation 
and dose across multiple dose groups, along with the large amount of variability in the 
measured ADA S/N ratios (as indicated by the large standard deviations) strongly 
suggests that using the measured ADA S/N ratios along with the change in clearance to 
predict ADA formation is a more suitable approach for our study rather than simply using 
cumulative dose. 
Kcomplex is a measurement of the mAb1-ADA complex binding and subsequent 
elimination.The kcomplex parameter was informed by the increase in clearance not 
explained by clearance in an ADA negative individual and is the rate at which the ADA 
binds to the mAb1 and eliminates it; representing a second order elimination pathway for 
mAb1 in our model and study. Kcomplex only works in one direction of binding and 
eliminating the mAb1, without a rate of unbinding of the mAb1, as seen in other models, 
like Chen’s model, where affinity maturation was estimated through another parameter 
(koff), which estimates the rate at which the therapeutic protein dissociates from the 
ADA.[146] Estimating the affinity maturation of each individual’s immune response 
would be ideal, but due to our sparse sampling of ADA we lacked the data necessary to 
describe the affinity maturation of the immune response. Even though affinity maturation 
could not be captured, the affinity of the ADA for the mAb1 in each individual was 
captured by kcomplex. As could be expected, each individual’s immune response was 
different and lead to much variability in kcomplex, as reflected by the large BSV (129%). 
This variability was caused by the differences in ADA affinity for the mAb1, which is 
depicted in ??????????, where similar ADA magnitudes have been formed against mAb1, 
but one has a greater effect on the pharmacokinetics of the mAb1. This difference in 
affinity between each individual made it difficult to link a consistent ADA magnitude to a 
subsequent effect on the pharmacokinetics of mAb1, which lead us to use the method of 
informing the parameter kcomplex with the additional clearance not explained by CL in the 
ADA negative animals, a method which was successfully applied. 
The timing of the initiation of ADA response is represented in the model by Tlag ,
the time delay between the first administration of a dose and occurrence of ADA. The 
estimated Tlag for the three mAb1 doses was approximately 14 days. This is in line with 
the expectations, as it has been observed that the primary immune response matures  
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?
???????????? ??????????????????????????????? ?????
Average ADA formation in the non-immunomodulated subgroup for each dosing group. 
These averages didn’t include animals which were ADA negative.
?
???????????? ?????????????????????????????????????????????
Both individuals shown here have received the same dose of mAb1 (50 mg/kg). 
Displayed are the observed data. This is a good example of the disconnect between ADA 
magnitude and affinity/clearance. 
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within around 10 days after the first antigen challenge, as immune cells need this time to 
become activated and differentiate to produce antibodies.[156] Thus, our estimate of Tlag
appears to be consistent with previously reported experimental observations. The delayed 
ADA response can also be directly observed in ??????????, where ADA concentration 
rises significantly after two weeks of therapy. 
During our study and model building it became apparent that predicting ADA and 
its effects is not possible with limited covariates. In our study there was a difference in 
not only ADA response but also affinity between each individual, which made it difficult 
to link a consistent ADA cause and subsequent effect to the pharmacokinetics of mAb1. 
Therefore simply measuring ADA S/N or mAb1 concentrations will not allow one to 
predict the other. These vast differences in both ADA magnitude of response and affinity 
required us to use measured ADA S/N in concert with measured mAb1 concentrations to 
inform the parameters Kada and Kcomplex, both of which allowed us to model the effect 
ADA has on the pharmacokinetics of the mAb1 in our PK/ADA model. Without the 
measured mAb1 concentration and the ADA S/N magnitude we would not have been 
able to accurately model the pharmacokinetics of mAb1 and the effect of ADA on the 
PK, let alone predict and simulate what dose will cause what magnitude of reaction, what 
ADA magnitude will cause a certain clearance or what clearance is caused by a certain 
magnitude of ADA reaction. More research into what is predictive of an organisms 
potential to elicit an immune response in the presence of a potential antigen is required 
before a prediction of immunogenicity can be made for therapeutic proteins. 
An interesting phenomenon observed while developing the PK/ADA model was a 
decreased systemic exposure and consistent overestimation of the concentration-time 
profiles for mAb1 in rats treated with methotrexate in the medium and high mAb1 dose 
groups (????????????and?????). It has been demonstrated previously that Fc? receptor 
expression was down regulated in the presence of methotrexate.[157] This interaction 
could potentially be occurring in our study, and could potentially also affect the neonatal 
Fc receptor (FcRn), which could lead to a downregulation of FcRn, eliminating a key 
recycling mechanism for IgGs, causing an increase in the clearance of mAb1. To further 
explore, if this interaction could help explain our models discrepancy with our observed 
data we built methotrexate into the model as a categorical covariate on clearance (CL), 
and implemented as follows in ?????????????: 
?? ? ??? ? ?????????      ????????
where the parameter estimate for the methotrexate effect on clearance was raised to the 
ITX interaction switch which was either 1 or 0 depending on whether the animal received 
methotrexate or not, respectively. With the experimental methotrexate covariate built into 
the model, we were able to explain more of the discrepancy between the animals treated 
with methotrexate and those that were not as seen in ???????????. We did not add this 
interaction as a covariate into our final model, as there is not a study to justify its 
addition, but the interaction could certainly be explored in the future. 
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?
???????????? ????????????????????????????????????????? ???????????
Potential methotrexate interaction indicated by the circle.  
A. 50 mg/kg mAb1 dosing group 
B. 300 mg/kg mAb1 dosing group 
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?
????????????? ?????????????????????????????
Figure shows the statistically significant change in AUC between the 
tacrolimus/sirolimus treated group and the methotrexate (MTX) treated group. A 
decrease in AUC is indicative of an increase in clearance. This increase in clearance may 
potentially be due to methotrexates effect on FcRn recycling in these animals. 
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????????????? ?????????????????????? ???????
Figures displayed below are individual concentration-time profiles for the 50 mg/kg dose 
and the 300 mg/kg dose groups that received methotrexate. Model fit from final model 
shown in red, model fit after methotrexate covariate added shown in green and observed 
data in blue.  
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The simulations performed with our final model demonstrated the effect ADA has 
on the serum concentrations of mAb1 over time (???????????). By simulating different 
percentages of immunogenicity, we can see the effect ADA has on the average 
concentration-time profile for a study, as well as the overall systemic exposure to the  
biotherapeutic. In multiple dose toxicity studies, a goal AUC/exposure is required to 
evaluate the potential toxicity of a medication over time. In the simulation shown in 
???????????, the goal of the hypothetical multiple dose study was to evaluate any toxicity 
which could be seen at a high exposure to the mAb, deemed to be an exposure of 5 
mmol*h/L over four weeks. In this hypothetical study, 100 animals were necessary to 
identify any toxicity that might exist.  As seen in ???????????, a dose of 300 mg/kg will 
result in an exposure of 9 mmol*h/L in 100% of the animals. On the other hand, if 
immunogenicity is seen in the study, the number of animals required to reach the goal 
exposure will need to increase. In the simulations depicted in ???????????, a 
concentration-time profile for animals that did not form ADA or had a 100% incidence of 
ADA, dosed with 300 mg/kg of mAb1, are shown. Due to the variability in the animals’ 
immune responses, which were captured by our model and are now reflected in the 
simulation, some of the animals will still reach the goal exposure. This is important to 
note, as even though 100% of the animals had an immune reaction some will still reach 
the goal exposure. What our model and simulation can show is the number of animals 
which will reach the goal exposure in the presents of ADA, which can subsequently 
inform how many more animals will be necessary to have an appropriately powered 
toxicity study. In the case of the hypothetical toxicity study outlined above, 100 animals 
were necessary to identify any toxicity that might exist in the absence an immune 
reaction. In the presents of an immune reaction in every animal, our simulation showed 
that 42% of the animals will still reach the goal exposure. Therefore, in order to power 
the toxicity study appropriately in the presents of ADA, 240 animals will be needed at the 
300 mg/kg dose level. As the simulation shows, by modeling and appreciating 
immunogenicity’s effect on the pharmacokinetics of a mAb, we can gain a better 
understanding of how to design toxicity studies with the necessary power to identify any 
potential toxicity.  
Overall, this study simultaneously modeled the serial concentration-time profiles 
of a human monoclonal antibody as well as the corresponding ADA signal-to-noise 
measurements to provide a quantitative and continuous description of ADA’s effect on 
the pharmacokinetics and systemic exposure of mAb1.  This study also highlighted the 
high variability in the time course and intensity of an ADA reaction and the highly 
variable effect on a biotherapeutic’s concentration-time course. The methodology used in 
this study demonstrates a modeling strategy that can be applied to other therapeutic 
proteins to assess the effect of immunogenicity on their pharmacokinetics, as well as 
allowing for the simulation of the variability in exposure introduced by immunogenicity, 
aiding in the development of appropriately powered toxicology studies and a better 
evaluation of the PK of biotherapeutics in preclinical settings.  
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????????????? ???????????
Simulated data for a 1 month multiple dose study. Shown are concentration-time profiles 
for two simulations using the same dose (300 mg/kg). The red simulation represents the 
mean and 95% confidence interval from 2000 simulated individuals dosed with a mAb 
that is associated with 0% ADA formation across the population. The blue simulation 
represents the mean and 95% confidence interval from 2000 simulated individuals dosed 
with a mAb that is associated with a 100% ADA formation across the population. 
?
?
?
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Understanding the interdependent absorption, distribution, metabolism and 
elimination processes governing the pharmacokinetics of medications is complex. This 
complexity is increased by the ontogeny changes in drug metabolizing enzymes and 
transporters during the maturational process in the pediatric population. The ontogeny of 
drug metabolizing enzymes and their contribution towards differences seen in drug 
biotransformation have been widely studied and reviewed in the pediatric 
population.[158-161] However, studies regarding the ontogeny of drug transporters are 
still limited. What is known about the development of drug transporters stem mainly from 
rodent models. Currently, there are very few published studies on the ontogeny of human 
hepatic drug transporters during the early postnatal into childhood ages.[162] 
One such hepatic transporter is MRP2 (ABCC2). Human multi-drug resistance 
proteins (MRPs) belong to the C sub-family of the ATP-binding cassette (ABC) protein 
family.[163] This C sub-family consists of 13 members, nine of which are MRP1 through 
MRP9. MRP2 (ABCC2) is localized in the apical surface, predominantly in the 
canalicular membrane of hepatocytes, and the major physiological function of this protein 
is to transport conjugated metabolites into the bile canaliculus in the liver.[163] MRP2 
has been associated with the hepatobiliary transport of bile acids and bilirubin, as well as 
several therapeutic agents used in the pediatric population. Some of the pediatric 
pharmacotherapies include antibiotics, angiotensin II receptor antagonists, 
chemotherapeutics, and HIV protease inhibitors, namely valsartan, olmesartan, 
irinotecan, saquinavir, ritonavir, indinavir, and ceftriaxone.[164, 165] In adults, the 
deficiency of MRP2 occurs in Dubin-Johnson syndrome.[166] Dubin-Johnson syndrome 
clinically results in an increase in conjugated bilirubin, which turns the liver black, but is 
typically benign in nature. The same cannot be said in the case of the transport of 
medications. If a medication relies upon MRP2 as a significant source of their clearance, 
a deficiency in MRP2 can lead to potential toxicities as the drug builds up in the patient.  
An example of a MRP2 related medication toxicity is seen with ceftriaxone. 
Ceftriaxone is a third generation cephalosporin antibiotic often used in the pediatric 
population to treat lower respiratory infections, meningitis and acute otitis media. It has 
been shown in previous pharmacokinetic studies that approximately 33% of the drug is 
eliminated unchanged in the bile through MRP2.[167, 168] With a significant amount of 
the drug’s elimination relying on MRP2 transport, problems may be associated with a 
lack of MRP2 presence and activity. Indeed, there have been several clinical reports of 
ceftriaxone related toxicities, such as biliary sludging or pseudolithiasis in the pediatric 
population.[169, 170] Pseudolithiasis is secondary to a high concentration of ceftriaxone 
in the liver which forms an insoluble salt with calcium in the bile. In cases where high 
doses of ceftriaxone are given, this risk of ceftriaxone induced cholestasis drastically 
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increases.[171, 172] The ontogeny of MRP2 is not well understood in humans, and the 
administration of ceftriaxone at the typically used doses in the pediatric population, 
particularly in newborns and infants whose drug clearance mechanisms are still 
developing, may lead to an accumulation of ceftriaxone in the hepatocyte and thus 
increase the risk of cholestasis. 
The aim of this study was to evaluate the effect of MRP2 ontogeny on the 
pharmacokinetics of a model drug, ceftriaxone, using a model-based approach. To 
accomplish this task, nonlinear mixed effects modeling was applied to integrate 
previously generated data on variations in MRP2 expression from neonates to adults, 
pharmacokinetic data on ceftriaxone in normal and MRP2 deficient rodents, and human 
pharmacokinetic data in pediatric and adult patient. Once the model was developed and 
qualified, it was used to model and simulate the effect of various dose levels and levels of 
MRP2 expression on the concentration-time profile of ceftriaxone. The results of the 
model provide additional insight into safe and efficacious dosing in pediatric patients 
with various MRP2 expression levels.  
Ceftriaxone was chosen as model drug for this study, not only because of the 
potential for toxicity in the pediatric population, but also due to its reliance on only two 
main mechanisms of clearance, which makes it an ideal medication to evaluate ontogeny 
effects. Ceftriaxone is primarily eliminated by MRP2 located on the canalicular 
membrane of hepatocytes and through renal excretion.[173] Ceftriaxone is not 
metabolized to any relevant extent, and this lack of metabolism helped to reduce the 
number of variables required to take into consideration when modeling MRP2’s effect on 
ceftriaxone in adult and pediatric patients, allowing us to focus on the transporter 
maturation as the primary determinant.  
????????
?
The following analyses for the determination of the ontogeny of the relative 
MRP2 protein expression in pediatric liver specimens and the pharmacokinetic study of 
ceftriaxone in normal and TR- Wistar rats were performed by Dr. Lisa Tang at the 
University of Tennessee Health Science Center.[174] The data generated from these 
experiments form the basis for the model-based analysis of the impact of MRP2 ontogeny 
on the pharmacokinetics of ceftriaxone in pediatric patients. 
?
????????????????????? ???????????????????????
?
Human pediatric liver tissues were acquired from two main sources – St. Jude 
Children’s Research Hospital (SJCRH, Memphis, TN) and the Medical College of 
Wisconsin (MCW, Milwaukee, WI). The samples from SJCRH (n = 72) originated from 
the Liver Tissue Procurement and Distribution System (University of Pittsburgh, 
Pittsburgh, PA, funded by National Institutes of Health Contract N01-DK-9-2310) and 
from the Cooperative Human Tissue Network (University of Alabama, Birmingham, AL, 
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funded by the National Cancer Institute). Samples from MCW (n = 67) originated from 
the Brain and Tissue Bank for Developmental Disorders, University of Baltimore and 
University of Miami (National Institute of Child Health and Human Development 
contract N01-DK-8-3284). All samples were collected from donors less than twelve years 
of age. The SJCRH samples were obtained from living donors either through biopsy or 
within one hour of cross-clamping in the case of organ donors. Harvested tissue was 
immediately flash frozen in transplant solution. Demographic information on the donor 
population and health status is provided in ?????????. 72 patients were used for protein 
analysis from the SJCRH samples. MCW samples were obtained from deceased donors 
and all tissues were used for MRP2 protein analysis. The postmortem samples from 
donors with disease processes that could potentially involve liver damage were excluded 
from the study. Demographic information for the MCW samples is provided in ?????????
???. The tissue membrane isolation and Western blotting procedure used for relative 
MRP2 quantification are summarized in Lisa Tang’s dissertation Age-Associated Hepatic 
Drug Transporter Expression and Its Implications for Pediatric Pharmacotherapy.[174] 
?????????????????????????????????????????????? ???????????????????
Eight-week old male Wistar (Hsd:WI, n = 7) and Mrp2 deficient TR- 
(HsdAmc:TR-Abcc2, n = 6) rats received a single intravenous injection of 100 mg/kg 
ceftriaxone sodium. Serial blood samples were obtained at 10 pre-defined time point for 
up to 6 hours post dose, and ceftriaxone plasma concentrations were determined high 
pressure liquid chromatography with UV detection. Excreted ceftriaxone amounts were 
also determined in urine and feces.  
The details on the pharmacokinetic study of ceftriaxone in normal and Mrp2 
deficient rats as well as the applied bioanalytical methodology for ceftriaxone 
quantification are described in Lisa Tang’s dissertation Age-Associated Hepatic Drug 
Transporter Expression and Its Implications for Pediatric Pharmacotherapy.[174] 
?????????????????????????? ?????????????????????????????????????? ???????????
???????????????????
?
In order to identify ceftriaxone concentration-time profiles reported for adult and 
pediatric patients of different age reported in the literature that could be used as a 
reference point for our model-based analysis, an electronic literature search was 
performed. PUBMED (Medline, using MeSH headings and text words) was searched 
from the early 1980’s (the decade ceftriaxone was being developed) to present; EMBASE 
(subject headings and text words) was searched from the early 1980’s to present. All 
databases were searched between Sept. 1 and 27, 2016.  
Studies were included that recruited patients commencing intravenous ceftriaxone 
treatment. We included both adult and pediatric studies. A study had to report all of the 
following measures: drug dose, concentration-time profiles, patient weights and ages.  
72
??????????? ??????????????????????? ??????????????????????????????????????
???????????????????????????????? ????????????????
????????????? ?? ?????????? ????????
???? ?????
A (<0.7 yrs) 9 0.53±0.18
B (0.7 - <3 yrs) 19 1.69±0.45
C (3 - <6 yrs) 12 3.83±0.83
D (6-12 yrs) 22 8.38±2.04
???????
Male 29
Female 22
Unknown 11
?????
Caucasian 35
Black 7
Others 6
Unknown 14
???????????????
Normal 36
Cirrhosis 10
Fibrosis 10
Acute Hepatitis 4
Necrosis 2
Data in table used with permission from Lisa Tang and Bernd Meibohm. Tang, L., Age-
Associated Hepatic Drug Transporter Expression and Its Implications for Pediatric 
Pharmacotherapy. Vol. Theses and Dissertations (ETD). Paper 260. 
http://dx.doi.org/10.21007/etd.cghs.2007.0312. . 2007, Memphis, TN: University of 
Tennessee Health Science Center. 
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??????????? ??????????????????????? ??????????????????????????????????????
??? ?????????????????? ???????????????
????????????? ?? ?????????? ???????? ?????????? ????????
???? ?????
A (<0.7 yrs) 43 0.23±0.15 18.1±8.21
B (0.7 - <3 yrs) 3 2.24±0.32 15.67±2.31
C (3 - <6 yrs) 7 4.22±0.96 17.43±9.43
D (6-12 yrs) 16 9.20±1.55 21±7.28
???????
Male 45
Female 23
Unknown 0
?????
Caucasian 43
Black 22
Others 3
Unknown 1
Data in table used with permission from Lisa Tang and Bernd Meibohm. Tang, L., Age-
Associated Hepatic Drug Transporter Expression and Its Implications for Pediatric 
Pharmacotherapy. Vol. Theses and Dissertations (ETD). Paper 260. 
http://dx.doi.org/10.21007/etd.cghs.2007.0312. . 2007, Memphis, TN: University of 
Tennessee Health Science Center. 
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Data included in several studies contained individual data sets, while other studies only 
reported average concentration-time profiles times for the individuals being analyzed. In 
order to prevent the inflation of between-subject variability, we multiplied the average 
concentration-time profiles based on the number of subjects whose data has been 
averaged. This approach attempts to balance the different information content between 
average and individual concentration-time profiles. Though, while fixing the issue of 
potential inflation of the between-subject variability, the opposite problem could occur, 
shrinkage of between subject variability. Therefore, in order to compensate and come to a 
reasonable estimate for between subject variability, we ran the model with the non-
duplicated patient averages data set and averaged both of the model runs between subject 
variability estimates. 
Due to the historic context when ceftriaxone was developed and introduced into 
clinical practice, it is worth noting that much of the ceftriaxone concentration data 
acquired from the literature was analyzed using the agar diffusion method, as HPLC was 
not a readily available technique in the early 1980’s. Agar diffusion measures the 
concentration of an antibiotic much like the well-known Kirby-Bauer antibiotic test. The 
difference being, instead of an antibiotic wafer being applied to bacteria swabbed across a 
culture plate, plasma from the patient is pipetted into a well within the agar plate 
uniformly filled with a bacterium susceptible enough to permit a clear-cut zone of 
inhibition with the lowest serum concentration of the antibiotic.[175] Once the patient’s 
serum is applied to the well, the antibiotic within the sample will diffuse from the well 
into the agar. This diffusion of the antibiotic into the bacteria filled agar will create a 
circular zone of killing, which can be measured and compared to the known calibration 
standards. There are limitations of using the agar diffusion method compared to HPLC to 
analyze antibiotic concentrations. These limitations are that agar diffusion is not be as 
accurate or precise as HPLC, as well as having a higher lower limit of quantification 
compared to HPLC. In addition, HPLC measures total drug concentrations, while the 
agar diffusion method as a bioassay is limited to unbound, pharmacologically active 
compound. The limitations of agar diffusion compared to HPLC are highlighted in a 
study done by Perea et al. investigating voriconazole levels in human plasma.[176] In this 
study, agar diffusion method was neither as precise as HPLC, with a precision of 12.1% 
compared to 3.5% for HPLC, nor as accurate as HPLC, with an accuracy of 1.28%
compared to 0.81% for HPLC.[176]  
Although the agar diffusion method has limitations in the precision, accuracy and 
LLOQ compared to HPLC when analyzing data, these differences did not have a 
discernable effect on the data collected using this technique. When comparing dose 
normalized data in the studies using different methods of measuring ceftriaxone 
concentration, the areas under the plasma concentration-time curves between the study 
groups did not differ significantly, as seen in ??????????. Therefore, we felt comfortable 
using data obtained with both methods in our subsequent analysis. 
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?
???????????? ?????????????? ?????????????????????????????? ????????????
Average AUC comparison of ceftriaxone analyzed by HPLC and ceftriaxone analysis 
done by agar diffusion method. Average AUC were calculated after a single dose of 
ceftriaxone of a 24 hour period. 
?
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????????????????????????????????????????????????????????????? ???? ???????????
?????????????????????????????????
?
??????????????????
?
Model development was guided by a sequential approach of fitting a model first 
to the preclinical pharmacokinetic data obtained in the wild-type and Mrp2 deficient rats, 
followed by the analysis of the pharmacokinetic data obtained for adults, and lastly the 
analysis of ontogeny data in pediatric populations (??????????). This approach allowed us 
to effectively elucidate the effect of Mrp2 on the concentration-time profile of ceftriaxone 
in rats before moving into human data. Once the percent contribution of Mrp2 to the 
clearance of ceftriaxone was determined in the rat model the same percent contribution 
was used to inform the human model going forward. Modeling the adult data helped to 
determine ceftriaxone clearance and volume parameters and their between-patient 
variability in humans. Subsequently, the ceftriaxone pharmacokinetic parameter estimates 
in adults, the contribution of Mrp2 to the total clearance of ceftriaxone from the rat study, 
and the ontogeny data on relative MRP2 expression in the pediatric population were 
integrated to predict ceftriaxone concentration-time profiles in the pediatric population. 
The prediction, rather than model fitting, for the ceftriaxone concentration-time profiles 
in children and comparison with literature-reported data can be viewed as an external 
validation of the approach to integrate animal pharmacokinetic data, human 
pharmacokinetic data, and human ontogeny data on MRP2 expression to predict the 
impact of maturational changes in MRP2 expression on the pharmacokinetics of 
ceftriaxone in pediatric patients. 
??????????
?
The plasma concentration–time profiles of ceftriaxone for each individual animal 
were simultaneously analyzed by nonlinear mixed effects modeling (NONMEM) 
(version VII, ICON Development Solutions). The first order conditional estimation 
(FOCE) method was used for estimation of model parameters.  
??????????????????????????? ???????
?
The pharmacokinetics of ceftriaxone were described using traditional 
compartmental pharmacokinetic modeling. One- and two-compartment models were 
tested. Estimated pharmacokinetic parameters were central volume of distribution, 
peripheral volume of distribution, as well as intercompartmental and elimination 
clearances. Structural models were compared using Akaike’s information criterion (AIC), 
defined as follows: AIC = −2LL + 2p, where −2LL is the twice the negative log-
likelihood of the model and p is the number of model parameters that were estimated.  
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?
???????????? ???????????????????????????????????? ??????????????????????????????
?????????????????????
?
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?????????????????????????? ???????
?
The interindividual variability in pharmacokinetic parameters were described 
using an exponential model, as follows in ????????????:
?? ?? ???? ??????       ???????
where θi is the estimated individual parameter, θTV is the typical value of the parameter 
and ηi is the random effect for the ith patient. The values of ηi were assumed to be 
normally distributed, with a mean of zero and variance ω2. Correlations between random 
effects were tested. Additive, proportional and mixed additive– proportional residual 
error models were tested.  
???????????????????
?
The model building for both preclinical and human models was guided by 
standard diagnostic plots and plausibility of the parameter estimates. Interindividual, 
residual and covariate models were compared using −2LL and AIC. The model with the 
lowest significant −2LL value, assessed by a likelihood ratio χ2 test, and the lowest AIC, 
was selected. The individual influence of each covariate on each realistic 
pharmacokinetic parameter was tested using the likelihood ratio test with α = 0.05 
(change in OFV≥3.84). The number of selected covariates was low, so no stepwise 
forward/backward covariate selection was needed. The covariates were kept in the final 
model if their influence was significant for α = 0.01 (change in OFV≥10.83) with an 
improvement in between subject variability of greater than 10%. 
????????
?
The model-based analysis of the impact of MRP2 ontogeny on the 
pharmacokinetics of ceftriaxone in pediatric patients used datasets from multiple sources. 
The MRP2 ontogeny data in humans, as well as the plasma concentration-time profiles of 
ceftriaxone in wild-type and Mrp2-deficient rats the rat data were previously generated 
by Dr. Lisa Tang in the laboratory of Dr. Bernd Meibohm at The University of Tennessee 
College of Pharmacy.[174] The ceftriaxone concentration-time profiles in pediatric and 
adult populations were obtained from literature sources.  
The observed ceftriaxone concentration time-profiles for the pharmacokinetic 
study in rats, for the adult data collection and the pediatric data collection are shown 
along with the model predicted concentration-time profiles for each group in ??????????.  
A total of 13 rats were included in the ceftriaxone pharmacokinetic study, six Mrp2 
deficient TR- rats and seven wild-type Wistar rats. ????????? shows the measured 
systemic exposures (area under the plasma concentration-time curve [59]), and the 
percentage of the ceftriaxone dose excreted in urine and feces over 24 hours. 
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?
?
???????????? ???????????????????????????? ????????????
Ceftriaxone was administered intravenously. The dotted lines represent the 5 and 95% 
simulated visual predicted check concentrations over time. A). Ceftriaxone 
concentration-time profiles for both wild type and TR- rats. (Dose 50 mg/kg) The solid 
lines are the mean observed concentration-time profiles. The dashed lies represent the 
mean simulated concentration over time. B). Ceftriaxone concentration-time profiles for 
adults. (Dose 1000-2000 mg) The solid line represents the mean simulated concentration 
over time. The dark circles represent the observed concentrations. C). Ceftriaxone 
concentration-time profiles for pediatric population (age range: 2 days-5.8 years) (Dose 
50 mg/kg). The solid line represents the mean simulated concentration over time. The 
dark circles represent the observed concentrations. 
?
?
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??????????? ????????????????????????????????????????????????????????? ??
????????????????
?????????? ??????????????? ?????????
CLT (L/hr/kg) 0.279±0.090 0.189±0.050
CLr (L/hr/kg) 0.076±0.050 0.123±0.050
AUCinf (mg*hr/L) 396±148 570±182
% Urine (24 hrs) 25.5±12.0 64.5±17.0
% Fecal (24 hrs) 18.5±16.0 0.0±0.0
???: Total Clearance 
???: Renal Clearance 
Data in table used with permission from Lisa Tang and Bernd Meibohm. Tang, L., Age-
Associated Hepatic Drug Transporter Expression and Its Implications for Pediatric 
Pharmacotherapy. Vol. Theses and Dissertations (ETD). Paper 260. 
http://dx.doi.org/10.21007/etd.cghs.2007.0312. . 2007, Memphis, TN: University of 
Tennessee Health Science Center. 
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The pharmacokinetics of ceftriaxone was best described using a two-compartment 
model with intravenous infusion, with an inter-compartmental clearance Q and clearance 
from the central compartment CL (??????????).  
The steps within the modeling strategy used to elucidate MRP2’s contribution to 
pediatric ceftriaxone exposure are outlined in ??????????.  
Modeling the rat data from Dr. Lisa Tang’s study was the first step, and allowed 
for the estimate of MRP2’s contribution to the total clearance of ceftriaxone. By 
modeling both the wild-type and TR- rats’ ceftriaxone concentration data I was able to 
identify MRP2’s contribution to the total clearance, which would be applied to predict 
pediatric ceftriaxone concentrations. 
When modeling the concentration-time profiles in rats, two covariates were found 
to be significant, as indicated by a drop in objective function value (OFV) of 3.84 or 
greater. The two covariates were weight and Mrp2 expression. Weight was a continuous 
covariate, while Mrp2 expression was a binary covariate (present for wild-type Wistar 
rats, and absent for TR- rats). Weight was used as a continuous covariate, centered on the 
mean weight of all the animals in the study, for both clearance and the volumes of 
distribution. The structure of the covariate is seen in ????????????: 
??? ?? ???? ????
??
??????
?
??
      ???????
where WT is the weight of the individual animal, WTmean is the mean weight of the 
animals in the study and θc is the allometric scaling parameter. Mrp2 expression was a 
significant covariate for clearance (CL). The TR- rats naturally do not have Mrp2 
expression; hence will not be able to eliminate the ceftriaxone through the biliary duct. 
Therefore, Mrp2 expression was used as a categorical covariate for MRP2 mediated 
clearance (CLMRP2) in these animals, and implemented as follows in ????????????: 
?????? ? ???????? ? ????       ???????
where the parameter estimate for the typical value of clearance (TVCL) is multiplied by 
the parameter estimate of the percent contribution of MRP2 ?????????, with MRP2 
representing a switch that indicates whether MRP2 is expressed (Wild-type; MRP2=1) or 
not expressed (TR-; MRP2=0). The contribution of MRP2 as a covariate is incorporated 
into the overall clearance in ???????????? as follows:  
?? ? ??? ? ????? ? ????????? ? ????? ? ??? ? ???? ? ????????? ? ?????
???????
In ????????????, the parameter estimate for the typical value of clearance (TVCL)
is multiplied by three different clearance percentages, which are subsequently added 
together to make the overall clearance. The first clearance percentage is multiplied into  
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?
???????????? ?????????????????????????? ?????
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the typical value of clearance and represents the percent contribution of renal clearance 
??, which was obtained from the urine data collected in the wild-type rats and fixed to 
25.5% (?????????). The second clearance percentage multiplied into the typical clearance 
is the percent contribution of MRP2 ????????, which was discussed in the previous 
paragraph. The last clearance percentage term multiplied into the typical value of 
clearance is the ‘unaccounted’ clearance not captured by renal or biliary excretion. In the 
pharmacokinetic study in rats, both urinary and fecal output were collected and analyzed, 
but both sources did not account for 100% of the drug elimination, therefore we 
incorporated a third term as contributor to the typical clearance, allowing for an accurate 
estimate of MRP2’s contribution to ceftriaxone elimination of 59% (?????????).  
Once the contribution of MRP2 to the total clearance was identified through 
modeling the rat data, the next step of the methodology was to assess the ontogeny of 
MRP2 expression in order to identify the level of MRP2 expression through childhood 
development (??????????). To do this, liver specimens from a total of 72 patients were 
included in the analysis. The resulting MRP2 expression profile that has previously been 
reported is shown in ??????????.[174] All samples were collected from donors less than 
twelve years of age. The MRP2 data from this study was then fit to a maturation function 
(sigmoid hyperbolic model), which has been shown previously to be a versatile and 
widely applicable method to fit maturational processes in pediatric populations.[177] 
Hence, we applied this model to fit the MRP2 data to identify the level of MRP2 
expression throughout physiologic development. ???????????? describes the 
maturational process is as follows:  
MAT? ???
????
???????????????
?????
??????
where AGE is the age of the patient, HILL is the hill coefficient which best described the 
slope of the maturation profile and TM50 is the maturation half-time. The result of the fit 
indicated that the best fit had a hill coefficient of 3.51 and a ????????of 0.586 years old 
(Model fit seen in ??????????). This function will be used moving forward to predict 
pediatric ceftriaxone concentration. 
The last step of the modeling was to use the adult human data to model the 
ceftriaxone pharmacokinetics, the output of which was fixed to predict pediatric 
ceftriaxone concentration. For the population pharmacokinetic analysis of ceftriaxone in 
humans, data collected from literature included 8 adult and 53 pediatric patients. The 
adult data came from studies performed by Zhou et al., Meyers et al., Gobeaux et al. and 
from clinical trial data obtained from Hospira New Zealand and Roche.[167, 178-181] 
The pediatric data was obtained from studies conducted by Toyonaga et al., McCracken 
et al. and Schaad et al.[182-184] The ages ranged from 1 day to 70 months for the 
pediatric data included, equivalent to 0.00274 to 5.83 years (?????????).
The pharmacokinetics of ceftriaxone in adults was modeled using a two-
compartment structural model (??????????), which estimated the parameters clearance  
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??????????? ??????????????????????????? ???????????????????????????????????????
??????????????? ????????????? ???????????????????
?
?????????? ????????? ????? ?? ????? ??
CL (L/hr) 0.069 9.00 28.9
V1 (L) 0.105 148 31.3
V2 (L) 0.045 120 --
Q (L/hr) 0.020 12.0 --
MRP-2 CL (%) 59.0 16.0 --
Allometric scaling coefficients  
??=0.75 (CL) 
??=1.00 (V1 and V2) 
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?
???????????? ????????????????????????????????????????????????????? ????????????
?????????????? ?????????????????????????????
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??????????? ???????????????????????????????????
????????????????
??????
??????????
?????????
0.005-0.500 43
0.510-6.00 10
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(CL), intercompartmental clearance (Q), central volume (V1) and peripheral volume (V2) 
(?????????), which would be fixed to predict pediatric ceftriaxone concentration using 
the same 2-compartment model.  
Once the pharmacokinetic parameters were obtained from the rat model (MRP2 
clearance contribution), adults model (PK parameters) and maturation function (pediatric 
ontogeny function fit), each was used to predict pediatric ceftriaxone exposure. Each of 
the parameters in the 2-compartment model were fixed to the adult parameter estimates, 
shown in ?????????. The modeled maturation function (??????????) was incorporated 
into the two compartment structural model as a covariate for clearance (CL), as seen in 
????????????. The covariate structure incorporates ????????????, which is the 
maturation function, and multiplies it into the percent contribution of MRP2 (θ%MRP2)
identified in the rat modeling step (59%): 
?? ? ? ???
????
???????????????
?????
? ?????? ? ????? ? ??? ? ??????? ? ?????
???????
In this case, the switch that was used in Eq.4 for ceftriaxone pharmacokinetics in rats to 
turn on and off contribution of MRP2 to clearance was not used here, as the sigmoid 
hyperbolic model represents the relative expression of MRP2. Of note, MRP2’s 
contribution (??????) was assumed to be the same as in rats. The MRP2 in humans is an 
orthologue to the one in rats, but despite that, the contribution should remain the same. 
The second half of the covariate equation ?? ? ????????represents the remaining 
percentage of clearance not mediated by MRP2, which includes the renal excretion as 
well as other elimination pathways as represented in the model for rats as ‘unaccounted’ 
clearance.  
After we predicted the pediatric ceftriaxone concentration-time profiles, several 
other covariates were also tested in our model to help explain additional BSV. One of the 
covariates was weight. Weight was used as a continuous covariate for clearance, and it 
was centered on the mean weight of a typical adult (70 kg). The structure of the covariate 
model for weight was identical to ????????????, where WT is the weight of the 
individual patient, WTmean is the mean weight of a typical adult and θc is the allometric 
scaling parameter.  Another covariate identified was age’s correlation to the volumes of 
distribution in the pediatric population. Age was used as a continuous covariate centered 
on the mean age in adults (36.5 years) as seen in ????????????:
? ? ??? ? ?
???
??????
?
????
      ???????
where AGE represents the age of the patient, AGEAvg represents the average adult age 
and θAGE represents the parameter estimate of the power change in volume. 
The plots of predicted vs. observed measurements, as well as VPC show that the 
prediction described the data satisfactorily (???????????and???????????). The 
pharmacokinetic parameters estimated are summarized in ?????????.
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??????????? ??????????????????????????? ???????????????????????????????????
????????
?
?????????? ????????? ????? ?? ????? ??
CL (L/hr) 1.05 8.00 16.9
V1 (L) 5.33 6.00 16.9
V2 (L) 3.98 4.00 --
Q (L/hr) 2.47 9.00 --
Data obtained from multifocal published reports 
Allometric scaling coefficients  
??=0.75 (CL) 
??=1.00 (V1 and V2) 
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?
???????????? ??????????????????????????????????????????????
Ceftriaxone concentration-time profiles for pediatric population (age range: 2 days-5.8 
years) (Dose 50 mg/kg). The solid line represents the mean simulated concentration over 
time. The dark circles represent the observed concentrations. Dotted lines represent the 
95% CI for 2000 simulations. 
???????????? ????????????????????????????????????????????????????????????????
????????????????????????????????????????????? ?????
90
??????????? ??????????????????????????? ???????????????????????????????????????
??????????????????????????????????????????????????????????????????????????
?????????? ????????? ????? ?? ????? ??
CL (L/hr) 1.05 -- 20.4
V1 (L) 5.33 -- 33.8
V2 (L) 3.98 -- --
Q (L/hr) 2.47 -- --
Age Effect on 
Volume
-0.167 -- --
MRP2 CL (%) 31.4 19 --
Allometric scaling coefficients  
??=0.75 (CL) 
??=1.00 (V1 and V2) 
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???????????
?
We used pharmacokinetic modeling to investigate the effect MRP2 ontogeny has 
on the concentration-time profile of ceftriaxone in pediatric patients. Structurally similar 
models have been used by prior studies modeling the pharmacokinetics of 
ceftriaxone.[185, 186] Our pharmacokinetic model, similar to the previous models, is 
based on a two-compartment model with intravenous infusion and clearance from the 
central compartment. In contrast to previous studies, however, our model integrates 
preclinical and ex vivo molecular biology data obtained in several previous studies, as 
well as data from literature sources, in order to model and simulate ceftriaxone 
concentration-time profiles across different pediatric age ranges. 
In order to identify the contribution of MRP2 to the total clearance of ceftriaxone, 
Mrp2 deficient TR- and wild-type Wistar rats were given a single intravenous dose of 
ceftriaxone, and the resulting plasma concentration-time profiles were analyzed and 
modeled. The ceftriaxone concentration-time profile was best described using a two-
compartment model with first-order elimination rate, which is a common structural model 
used for ceftriaxone in rats.[187] The value of clearance, estimated in the present study as 
69 mL/hr, was divided into three components, with each route representing a relative 
percentage of elimination, as shown in ????????????. The relative contribution of each 
clearance route was defined by the pharmacokinetic study performed in wild-type and 
Mrp2-deficient rats and the subsequent model-based analysis. The percent of renal 
elimination was defined through assessment of the fraction of the dose excreted 
unchanged in the urine and was found to be 25.5% of the total clearance in the wild-type 
Wistar rats. The subsequent model-based analysis estimated the percent contribution of 
Mrp2-mediated biliary excretion to the total clearance as 59%.  This percentage 
contribution of Mrp2 estimated by the model agrees with the literature, which states the 
biliary clearance can contribute from 25-75% to the total clearance of ceftriaxone in 
rats.[188, 189] Our model also estimated that the third route of elimination had a relative 
contribution of 15.5%. Adding the third route of relative contribution to the clearance 
was required in this instance, as the TR- rats had an increase in renal clearance compared 
to the wild- type rats (0.123 L/hr/kg vs 0.076 L/hr/kg), as well as a total clearance that 
could not be explained by renal clearance alone, as seen in ?????????. In an ideal 
situation one would expect identical renal clearances, and in the case of TR- rats, a renal 
clearance that explained the total clearance. Instead, the TR- rats had an increase in renal 
clearance, and a total clearance that was greater than the renal elimination in those 
animals. This contradictory data may be explained by compensatory mechanisms, such as 
alternative renal transporters that more than likely exist in the TR- rats which have 
developed and or become contributors for extraction if substrate concentrations increase 
in the absence of Mrp2.[163, 190] Therefore, in order to account for additional clearance 
mechanisms, which may include intestinal transport and metabolism, a third contributor 
to total clearance was introduced into the covariate equation, as shown in ????????????.
In this equation, the percent contribution of both Mrp2 and renal excretion were 
subtracted from 100% and multiplied into the total clearance, in order to account for the 
clearance that was not captured by the urinary data or the difference in clearance caused 
by a lack of MRP2 expression.  
92
Once the relative contribution of MRP2 to clearance was established in rats, the 
next step was to establish a population pharmacokinetic model for adult ceftriaxone 
concentration-time data. Data from several studies in healthy adult patients given 
different doses of ceftriaxone through the intravenous route were analyzed and modeled 
using a two-compartment model with first-order elimination rate. This base model was 
found to be the most appropriate and is a common structural model used for ceftriaxone 
in humans.[185, 186] Ceftriaxone’s central volume of distribution (V1) and peripheral 
volume of distribution (V2) were estimated as 5.33 L and 3.98 L, respectively, values that 
have also been observed in other studies.[191] Intercompartmental clearance (Q) was 
estimated at 2.47 L/hr. The point estimate for clearance (CL) in the present study was 
1.05 L/hr, a value similar to what other studies have found in humans.[179, 191, 192] 
Due to the good agreement between the results of our population pharmacokinetic model 
and the available literature reports, we were confident to apply and fix these parameters 
when modeling and simulating pediatric data. 
The last step was to expand the two-compartment structural model to pediatric 
data on ceftriaxone disposition obtained from clinical studies in the literature. We first 
fixed the adult parameter estimates in our structural model and attempted to predict the 
pediatric data by simply scaling parameters based on weight-based allometric scaling, 
using the typically applied allometric exponents of 0.75 for clearance terms and 1 for 
volume terms.[193] As shown in ??????????, the adult parameters, even when 
allometrically scaled, over predicted the ceftriaxone concentrations encountered in 
pediatric patients. When evaluating covariates, we found that age was correlated to the 
volumes of distribution in the pediatric population. In response to this observation, we 
expanded the structural model with a covariate for both central volume and peripheral 
volume, as seen in ????????????. In ????????????, AGE represents the age of the 
patient, AGEAvg represents the average adult age and θAGE represents the parameter 
estimate of the power change in volume. Age also had an effect on the clearance of 
ceftriaxone, beyond what was captured by allometric scaling.  
In the infants, the clearance of ceftriaxone was over-predicted when only 
allometric scaling was applied. This observation was not unexpected as the ontogeny of 
MRP2 was not accounted for by allometric scaling. In order to effectively describe the 
influence of the ontogeny of MRP2 expression on the clearance of ceftriaxone in this age 
group, we fit a sigmoid hyperbolic model to the age-dependent relative MRP2 expression 
data previously generated in Dr. Meibohm laboratory as indicated in ???????????? and 
??????????.[174] 
We subsequently integrated both, the hyperbolic sigmoidal maturation curve fit 
and the percent contribution of MRP2 to build and inform our covariate model for 
clearance as shown in ????????????? and ???. ???????????? represents the maturation of 
MRP2 expression in pediatric patients, and it is multiplied into the percent contribution of 
MRP2 to clearance (??????) in ????????????, which is added to (1- ??????) representing 
the remaining percent contribution to the total clearance by non-MRP2 mediated 
elimination processes. Within these equations, we fixed the relative contribution of  
93
???????????? ?????????????????????????????????????????????????????? ????????
??????????????????????????????????????????????????????????????
Observed Ceftriaxone Concentration versus the Model Predicted Ceftriaxone 
Concentration for Pediatric and Adult Populations. Structural model with only allometric 
scaling being applied to each parameter (V1, V2, CL and Q). 
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MRP2 to the estimate obtained from the rat study (59%), along with incorporating the 
fitted sigmoidal hyperbolic maturation equation. The total clearance remained fixed to the 
adult value. Integration of the contribution of MRP2 ontogeny to the clearance of 
ceftriaxone further improved the correlation between model predicted ceftriaxone 
concentrations and the observed values in the pediatric patient population, as seen in 
??????????. Unfortunately, the model fit was not adequate. The clearance was under 
predicted now in the infant population, as indicated by the poor fit of the VPC to the 
observed data and skewed distribution of individual predictions (ETA) from the 
population estimate for clearance, shown in ?????????????and?????. Therefore, the rat 
data on MRP2 contribution may not be predictive of what happens in infants.  
We decided that we could not rely on the rat data. Instead of using the rat data for 
MRP2 contribution, we estimated MRP2’s relative contribution based on the adult and 
pediatric data, and the hyperbolic sigmoidal maturation model for the ontogeny of MRP2 
expression. The same structural model and covariates were applied, and the relative 
contribution of MRP to the clearance of ceftriaxone was estimated to be 32%, instead of 
the 59% estimated from the rat data. A 32% contribution of biliary elimination is 
agreeable with the literature,[191] more accurately predicted the clearance in infants 
based on the adult data, and lead to the correct ceftriaxone concentration-time profile 
predictions in infants as indicated by the VPC and the normal distribution of individual 
predictions (ETA) from the population estimate for clearance.(????????????and?????).  
In summary, we used pharmacokinetic modelling to investigate the effect MRP2 
ontogeny has on the concentration time profile of ceftriaxone using multiple studies and 
literature. Our model was able to capture ceftriaxone’s pharmacokinetics, and MRP2’s 
contribution to its clearance in adult and pediatric population. This study highlights 
MRP2’s contribution to clearance of ceftriaxone, as well as its ontogeny. The 
methodology used in this study demonstrates a modeling strategy that can be applied to 
other transport proteins or drug metabolizing enzymes to assess the potential effect their 
ontogeny may have on the pharmacokinetics of a medication, aiding in the development 
of appropriate dosing protocols in the pediatric patient populations. 
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???????????? ?????????????????????????????????????????????? ???????????????
???????????????????????????????????????????????????????????????
Structural model plus the age covariate model for V1 and V2, as well as the maturation 
covariate model for CL built in. MRP2/Biliary contribution is fixed to 59% of total 
clearance (Rat predicted percent contribution). 
????????????? ????????????????????? ?????????????????????????????????????? ????
?????????????????????????????????
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?
????????????? ???? ????????????????????????????????????????????????????????
???????????????????????????????????????? ???????????????????? ?????????????????
??????????????????????????????????????
Model is consistently under-predicting clearance for a large population of individuals. 
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?
????????????? ???? ????????????????????? ??????????????????????????????????
???????????????????????????????????????? ???????????????????? ??????????????????
Clearance estimates are now representative of the true population distribution. 
?
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Advances in the technology and development of monoclonal antibodies (mAbs) 
have provided vast improvements in modern medicine. The preclinical development of a 
fully human or humanized mAb can be challenging, as dynamic changes in physiologic 
processes during pharmacokinetic and toxicological research of mAbs cause variability in 
drug disposition and elimination processes. The focus of this dissertation is on the 
variability in pharmacokinetics caused by ADA formation and ontogeny changes in a 
transport protein. These dynamic and variable changes affect decisions on toxicology 
assessments and first-in-human dosing in drug development, as well as pediatric dosing 
of therapeutic drugs. Therefore, new methods of preventing variability in these processes 
and accounting for the variability were explored in order to better understand the 
pharmacokinetics of the affected therapeutic drugs.  In this dissertation I hypothesized 
that there are physiologically associated changes in the immune system and age-
associated changes in transport protein expression which can lead to significant changes 
in pharmacokinetic parameters of therapeutic drugs, and that we can control for these 
dynamic changes through either preventing or limiting them through immunomodulatory 
therapies and or accounting for them through model-based pharmacometric approaches. 
This overall goal was accomplished in three examples:: 1.) The development of new 
immunomodulation treatment modalities, which will limit or prevent ADA formation in 
preclinical studies, 2.) The development of a pharmacometric PK-ADA modeling 
strategy that accounts for the effect of ADA formation on the systemic exposure of 
mAbs, and 3.) The development of a systems pharmacology modeling strategy that 
accounts for a transport protein’s ontogeny and the variable and dynamic effect on a 
substrate that is a therapeutically used drug. In order to limit or prevent ADA formation 
towards a mAB in preclinical species, I tested two different immunomodulation 
strategies. In addition, I investigated the effect of an ADA forming immune response on 
the pharmacokinetics of a therapeutic mAb using a pharmacometric modeling approach. 
Lastly, I demonstrated a systems pharmacology modeling approach to assess the potential 
impact of maturational changes in transport proteins on the pharmacokinetics of the 
model drug ceftriaxone, a third generation cephalosporin antibiotic. 
We confirmed our hypothesis that the use of immune suppressant regimens will 
mitigate an ADA response to a fully-humanized mAb in preclinical animal studies, and 
we successfully lowered antibody responses in animals to humanized therapeutics. This 
reduced the variability in the therapeutic mAb exposure in the systemic circulation. The 
combination of tacrolimus/sirolimus was able to reduce ADA incidence and magnitude at 
each studied dose level effectively. Tacrolimus/sirolimus treatment more than halved 
ADA incidence across all dose levels and the maximum ADA signal-to-noise ratio fell to 
less than 1% of that of the non-immunomodulated group.  Methotrexate elicited at least a 
50% drop in ADA incidence in the higher dose groups, although it was not as effective in 
the lower dose groups.  This less efficacious immune suppression by methotrexate at 
lower dosages could be due to the insufficient frequency of immune suppressant 
administration, and/or the possibility that insufficient mAb was present in the circulation 
to induce methotrexate-mediated tolerance. To this end, utilizing additional cycles of 
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methotrexate along with higher doses of the therapeutic mAb may further mitigate anti-
drug immune responses. Additional studies will be essential to streamlining 
immunomodulatory drug use in preclinical drug development.  Studies evaluating 
different doses and dosing frequencies of the current therapies used in this dissertation, as 
well as a broader selection of immunosuppressant drugs and techniques could further aid 
in the selection of an optimal immunosuppressive regimen to help reduce mAb 
pharmacokinetic variability caused by immune reactivity.   
The preclinical pharmacokinetic evaluation of a therapeutic mAb is complicated 
by immune responses from the animals being tested. A pharmacometric modeling 
approach was applied to investigate the dynamic and variable effect ADA formation has 
on the concentration-time profile of a mAb. Our PK/ADA model was based on the 
assumption that the drug disposition is affected by ADA-mediated clearance. The 
performed study took simultaneous and serial measurements of both the concentration of 
mAb, as well as the ADA signal-to-noise level. These measurements informed a 
PK/ADA model, which was built to model the data and simulate the ADA effect on the 
mAb. The mAb pharmacokinetic profile was best described using a two-compartment 
model with first-order elimination rate and a first-order absorption process. The ADA 
exposure and effect was described by a series of delay compartments which represented 
the time it took, after the first mAb dose, for ADA to form and eventually move into the 
central compartment. Once in the central compartment the ADA was able to bind to the 
mAb and eliminate it as a mAb-ADA complex.  The magnitude and increase in clearance 
caused by the ADA responses are described in the model by the parameters 
Kada and kcomplex, respectively, while the timing of the ADA response is described by the 
parameter Tlag. Kada represented the molar rate of ADA moving into the delay 
compartments, and eventually into the central compartment and was dependent on the 
measured ADA signal-to-noise ratios. The timing of the initiation of ADA response is 
depicted in the model by estimating Tlag, the ADA lag time. Kcomplex was a second-order 
rate constant that captured the rate at which ADA bound to mAb and was thereby 
eliminated from the systemic circulation. This parameter was informed by the increase in 
mAb clearance beyond clearance of the mAb in ADA negative animals. It was this 
parameter that had the most between subject variability (BSV). The high amount of 
unexplained BSV on kcomplex was a weakness of the study design, which was captured by 
this modeling strategy. For future studies, I would recommend increasing the number of 
ADA sampling points, with a focus on the second, third and fourth week of dosing. This
will help to delineate the change in affinity over time and allow for the estimation of 
affinity maturation in the ADA reaction. Also capturing additional potential covariates, 
like HLA subtype, in each of the subjects may help to account for the BSV on kcomplex.
Despite the weaknesses, by applying this modeling approach, I was able to capture the 
pharmacokinetics of the mAb, as well as ADA’s effect on the mAb concentration-time 
profile. The model also allowed the simulation of ADA production in preclinical species 
receiving multiple doses of a mAb, and the subsequent effect that ADA formation will 
have on the mAb profile. The methodology used in this study demonstrates a modeling 
strategy that can be applied to other therapeutic mAbs. This methodology allows the 
assessment of the effect of immunogenicity on the pharmacokinetics of a therapeutic 
mAb, as well as allowing for the simulation of the variability in mAb systemic exposure 
100
introduced by immunogenicity, which will aid in the development of appropriately 
powered toxicology studies and allow for a better evaluation of the pharmacokinetics of 
novel therapeutic mAbs in the preclinical setting.  
Understanding the absorption, distribution, metabolism and elimination of 
therapeutic drugs is complex. This complexity is increased by the ontogeny-related 
changes in transport proteins during the maturational process in the pediatric population. 
A systems pharmacology modelling approach was applied to investigate the dynamic and 
variable effect the ontogeny of MRP2 has on the clearance of a substrate drug, 
ceftriaxone, in pediatric subjects. This modeling strategy can also be used to evaluate 
ontogeny changes in other biochemical transposition proteins, and their effect on the 
pharmacokinetics of other therapeutically used compounds, small molecule drugs as well 
a therapeutic proteins such as mAbs. The model developed during my dissertation 
research applies data obtained in several previous studies, as well as data from literature 
sources to model and simulate ceftriaxone concentration-time profiles across different 
age ranges. To identify the contribution of MRP2 to the total clearance of ceftriaxone, 
wild-type Wistar rats and Mrp2-deficient TR- rats received a single intravenous dose of 
ceftriaxone, and the resulting plasma concentration-time profiles were measured, 
analyzed and modeled. I then developed a human population pharmacokinetic model for 
ceftriaxone and estimated adult human pharmacokinetic parameters using data collected 
from studies previously published in the literature. Once I had established MRP2’s 
contribution to clearance using the rat study and determined the adult pharmacokinetic 
model parameters, I fixed the adult parameter estimates in our structural model and 
allometrically scaled the parameter estimates based on body weight to predict ceftriaxone 
concentration-time profiles in pediatric patients of different age. When using the 
allometric approach alone, it leads to an overprediction of the concentration-time profiles 
of ceftriaxone in the pediatric population. With the allometric scaling approach the 
volumes of distribution were under predicted and clearance was over predicted. MRP2’s 
ontogeny was not accounted for by allometric scaling, and in order to effectively describe 
the ontogeny effect of MRP2 in this age range I integrated the ontogeny data for MRP2 
protein expression in human liver obtained in a previous study performed in our 
laboratory to fit a sigmoid hyperbolic model that described the maturation process of 
MRP2 expression. I used both the MRP2 ontogeny data, which informed the hyperbolic 
sigmoidal maturation curve fit, and the percent contribution of MRP2 to total ceftriaxone 
clearance, identified in the rat study, to build and inform our covariate model for the 
clearance of ceftriaxone. With this strategy, the model fit improved, but the clearance was 
under predicted in the infant population using the rat MRP2 relative contribution to 
clearance. It was identified that the rat data, which I used to ascertain MRP2 contribution, 
may not be predictive of what happens in infants. Therefore, we estimated MRP2’s 
relative contribution to ceftriaxone clearance in our established modeling framework. 
Another limitation in this study came from the different methodologies applied to analyze 
ceftriaxone concentration in the studies. The model included data analyzed with agar 
method and some with HPLC. Although the effect of the methods on the concentration 
analysis was not significant, variability was still introduced into the parameter estimates 
because of the different methods used. Despite the increased variability, the model was 
able to adequately capture the pharmacokinetics of ceftriaxone, and the contribution of 
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MRP2 to its clearance in the adult and pediatric population. The systems pharmacology 
modeling methodology used in this study demonstrates a modeling strategy that can be 
applied to other therapeutic agents, including mAbs, to assess the effect of ontogeny of a 
biochemical disposition process and the potential effect it may have on the 
pharmacokinetics of the affected drug, thereby aiding in the development of appropriate 
dosing protocols in the pediatric population. 
In summary, I have successfully determined an immunomodulation strategy that 
will help prevent ADA formation and the variable pharmacokinetics that are introduced 
in the presence of ADA. Furthermore, I also applied a pharmacometric modeling strategy 
to understand and account for the variability in pharmacokinetics caused by an immune 
reaction. Lastly, I demonstrated a systems pharmacology modeling method to account for 
ontogeny changes in a transport protein and the subsequent changes in the 
pharmacokinetics of the substrate. The results of these studies demonstrate that there are 
physiologic changes associated with the immune system and age-associated changes in 
biochemical disposition processes which can lead to significant changes in the 
pharmacokinetic behaviors of therapeutic agents, and that I was able to modulate and 
account for these dynamic changes through immunomodulatory therapies and through 
systems pharmacology modeling approaches. Moving forward these strategies can be 
applied to other therapeutic agents, including mAbs, to understand how dynamic changes 
that occur in study subjects will affect their pharmacokinetics. 
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